EIN Presswire: Pfizer Press Releases

Nanosmart(R) Pharmaceuticals Welcomes New Vice President Of R&D

Thu, 24 May 2012 12:00:00 +0000

Nanosmart(R) Pharmaceuticals Welcomes New Vice President Of R&D

PR Newswire

ORANGE COUNTY, Calif., May 24, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, Inc., a California corporation developing a novel drug-delivery platform for cancer pharmaceuticals, announced today that the company has added Dr. Paul Glidden as Vice President of Research and Development.

"Dr. Glidden has worked for over 20 years developing new chemical and molecular entities leading to over a dozen commercialized pharmaceuticals," said Dr. Smith. "His expertise and proven track record will be instrumental in accelerating and expanding NanoSmart's development program," declared Dr. Smith. "We're very pleased to welcome Dr. Glidden to our team."

Dr. Glidden has extensive experience with small molecule and biological therapeutic modalities. As founder, director and VP of Development of BioVascular, Inc., he developed Saratin for the treatment and prevention of intimal hyperplasia, and Anagrelide CR, a novel formulation with improved safety of a small molecule for the treatment of essential thrombycythemia. As VP of Development at Angiosyn, Inc (acquired by Pfizer), he was responsible for all non-clinical, manufacturing, regulatory, quality, and clinical activities for a recombinant protein with anti-angiogenic properties.

"Based on my personal experience with pediatric cancer in my own family, I have a deep interest in developing novel cancer pharmaceutical products that may help the children of other families," explained Dr. Glidden. "NanoSmart's immunoliposomal formulations are designed to more safely deliver the toxic drugs to the target cancer tissues while protecting surrounding healthy tissues. In addition, NanoSmart's platform opens up a multitude of targets using the same delivery system, including a range of rare, pediatric cancers."

Dr. Glidden holds a B.S. degree in Biochemistry and Biophysics from Oregon State University and a Ph.D. in Pharmacology and Toxicology from the University of California, Irvine.

ABOUT NanoSmart(R) Pharmaceuticals, Inc.

NanoSmart(R) Pharmaceuticals, Inc., a private biotechnology company, is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases. NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of cancer and other diseases. NanoSmart has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of its lead candidate drug products. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

For more information, visit www.nanosmartpharma.com

SOURCE NanoSmart Pharmaceuticals, Inc.

R&D Trends: Depression - Clinical attrition driven by mature market conditions

Thu, 24 May 2012 11:08:27 +0000

R&D Trends: Depression - Clinical attrition driven by mature market conditions

PR Newswire

NEW YORK, May 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

R&D Trends: Depression – Clinical attrition driven by mature market conditions

http://www.reportlinker.com/p0799259/RD-Trends-Depression-–-Clinical-attrition-driven-by-mature-market-conditions.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Several drugs have progressed through the pipeline for depression in recent years, including Pristiq (desvenlafaxine; Pfizer), Oleptro (trazodone extended release; Labopharm), and Viibryd (Forest) in the US, and Valdoxan (agomelatine; Servier/Novartis) in the EU. Despite the heightened competition within the marketplace, an abundance of drugs remain in the pipeline.Understand key dynamics in the R&D pipeline for new depression therapiesBenchmark novel and existing therapies using the target product profile identified by DatamonitorSupport R&D decision making by evaluating antidepressant clinical trial designs that have set a precedentEvaluate the most promising new pharmacological targets in early-stage developmentAccess Datamonitor's prediction of how the treatment landscape may change in the next 20 yearsThere are 46 separate programs across all stages of clinical development for depression, down from 66 in 2007 with a notably high attrition of early-stage projects. Reasons for this include promising new targets failing to yield an effective antidepressant, and big players such as GlaxoSmithKline switching its research focus.Although depleted, the early-stage pipeline still has the potential to change current treatment algorithms, which are dominated by monoamine reuptake inhibitors. Popular approaches include glutamate and neuropeptide receptor modulation. Datamonitor sees the future of treatment in depression as the specific targeting of treatment-resistant patients.Clinical trial design in depression is largely standardized. Although not required, head-to-head trials may allow for a more favorable label and explicit marketing claims. Datamonitor believes that future trials will be designed for regulatory approval in patients with treatment-resistant depression, or for use as an add-on to existing therapies.What are the key trends in the depression pipeline?What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?How will new antidepressant treatments evolve in the next 20 years?

OVERVIEWCatalystSummaryEXECUTIVE SUMMARYStrategic scoping and focusUpdate details: January 2012Datamonitor key findingsRelated reportsCLINICAL PIPELINE OVERVIEWOverview of the depression pipelineDatamonitor has identified 46 separate programs in clinical developmentEmerging features of the depression pipelineChanges in pipeline dynamicsCompanies involved in the depression pipelineDiscontinued pipeline drugs in depression54 distinct depression projects have been discontinued since 2010The vast majority of discontinuations happen either during preclinical testing or Phase II studiesNeuropeptide modulators and monoamine reuptake inhibitors head the list of discontinued projectsTARGET PRODUCT PROFILEComparator therapiesLexapro (escitalopram; Forest/Lundbeck)Target product profile versus current level of attainmentCLINICAL TRIAL DESIGN IN DEPRESSIONClinical trialsCommonly used clinical trial endpoints for depressionTypical trial designTrial length is commonly standardized to a duration of just 8 weeks Comparator trials can provide a compelling argument for using one drug ahead of anotherFuture developments in clinical trial designTreatment-resistant depression clinical trial designAdjunctive therapy clinical trial designINNOVATIVE EARLY-STAGE APPROACHESGlutamate receptor modulationNMDA receptor antagonists and partial agonistsMetabotropic glutamate receptor antagonistsTargeting neuropeptides for depressionBackgroundVasopressin receptor antagonistsNeurokinin receptor antagonistsTHE FUTURE OF TREATMENT IN DEPRESSIONSpecific targeting of treatment-resistant patientsA label for treatment-resistant depression will bypass competition with generic first-line antidepressantsTreatment-resistant depression is characterized by a large target population and substantial unmet needBiomarkers for depressionConsiderable variations in treatment outcomes existBiomarkers may have utility in identifying likely responders and improving treatment outcomesThe commercial appeal of reduced R&D spend and a competitive advantage is a bonusBiomarkers in clinical developmentBIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsAPPENDIXContributing expertsConferences attendedReport methodology

TABLES

Table: Products in clinical development for depression, January 2012

Table: Depression clinical pipeline, by mode of action and development stage, January 2012

Table: Discontinued pipeline drugs in depression, 2010–12

Table: Discontinued drugs formerly in development for depression, by mode of action and developmental stage, 2010–12

Table: Lexapro (escitalopram; Forest/Lundbeck) – drug profile in depression, 2012

Table: Defining the gold standard for depression: key clinical trial results for Lexapro

Table: Target product profile in major depressive disorder, 2012

Table: Comparison between the HAM-D and MADRS rating scales for depression

Table: Typical Phase III clinical trial design in major depressive disorder

Table: Key facts: Lexapro (escitalopram; Forest/Lundbeck) versus Cymbalta (duloxetine; Eli Lilly) comparator trial in major depressive disorder

Table: Key facts: Symbyax (fluoxetine and olanzapine; Eli Lilly) pivotal Phase III clinical trial

Table: Key facts: Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka) pivotal Phase III clinical trial

Table: Most promising innovative therapeutic approaches in depression, January 2012

FIGURESFigure: Depression clinical pipeline, by developmental stage, January 2012Figure: Depression clinical pipeline, by mode of action, January 2012Figure: Products in clinical development for depression, 2007, 2011, and 2012Figure: Modes of action in the depression pipeline, 2007, 2011, and 2012Figure: Depression pipeline, by developmental stage and company type, January 2012Figure: Big Pharma's involvement in the depression pipeline, January 2012Figure: Discontinued drugs formerly in development for depression, by developmental stage, 2010–12Figure: Modes of action of discontinued pipeline drugs and active pipeline drugs in depression, 2010–12Figure: Head-to-head clinical trial of Lexapro (escitalopram; Forest/Lundbeck) versus Celexa (citalopram; Forest/Lundbeck)Figure: Potential timeline for future depression therapiesFigure: Proportion of patients that display treatment-resistant depression (%) in the seven major markets, 2010Figure: BRITE-MD study of the Antidepressant Treatment Response Index as a functional biomarker for depressionCompanies mentioned Commerzbank AG, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Johnson & Johnson, Kewill plc, Telenor ASA

To order this report:Pathology Industry: R&D Trends: Depression – Clinical attrition driven by mature market conditions

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Auxilium Pharmaceuticals, Inc. and FCB I LLC File Lawsuit Against Watson for Infringement of Testim® Patents

Thu, 24 May 2012 11:00:00 +0000

Auxilium Pharmaceuticals, Inc. and FCB I LLC File Lawsuit Against Watson for Infringement of Testim® Patents

PR Newswire

MALVERN, Pa., and WILMINGTON, Del., May 24, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) ("Auxilium") and FCB I LLC ("FCB") announced today that they filed a lawsuit against Watson Laboratories, Inc. (NV); Watson Pharmaceuticals, Inc.; and Watson Pharma, Inc. (collectively, "Watson") for infringement of FCB's ten patents listed in the U.S. Food and Drug Administration's ("FDA's") Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book") as covering Testim^® 1% testosterone gel. The lawsuit was filed in the United States District Court for the District of New Jersey on May 23, 2012.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

Auxilium and FCB filed this lawsuit in response to a notice letter sent by Watson Laboratories, Inc. (NV) regarding its filing with the FDA of Abbreviated New Drug Application ("ANDA") No. 09‑1073 for a generic 1% testosterone gel product. This letter also stated that ANDA No. 09‑1073 contained Paragraph IV certifications, under 21 U.S.C. Section 355(j) of the Federal Food, Drug, and Cosmetic Act, with respect to the nine patents listed in the Orange Book on that date as covering Testim^®: U.S. Patent Nos. 7,320,968; 7,608,605; 7,608,606; 7,608,607; 7,608,608; 7,608,609; 7,608,610; 7,935,690; and 8,063,029. On May 15, 2012, a new composition patent covering Testim(U.S. Patent No. 8,178,518) issued. This patent is now also listed in the Orange Book and was included in the patent infringement lawsuit filed against Watson. In total, ten Testim patents are now listed in the Orange Book and are expected to expire on various dates ranging from April 21, 2023 through January 18, 2025. Auxilium and FCB remain committed to protecting their intellectual property rights, including their patent protection for Testim.

Under the Hatch-Waxman Act, as a result of the patent infringement lawsuit filed against Watson, final FDA approval of Watson's ANDA for its proposed generic version of Testim will be stayed until at least the earlier of 30 months from the date Watson's notice letter was received (i.e., October 13, 2014) or final resolution of the pending patent infringement lawsuit. Should Watson receive tentative approval from the FDA for its generic version of Testim before one of those events occurs, it would not be permitted to launch its generic product in the U.S. Watson will also not be able to launch a generic version of Testim in the U.S. until it receives the necessary final approval of its ANDA from the FDA, which includes proving to the FDA that Watson's proposed generic product is comparable to Testim in dosage form, strength, route of administration, quality, performance characteristics, and intended use.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim^® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX^® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord. GlaxoSmithKline LLC is expected to co-promote Testim with Auxilium in the U.S. beginning in the third quarter of 2012. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Pfizer has marketing rights for XIAPEX^® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, phase IIa of development for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

About FCB

FCB I LLC is an indirect, majority-owned subsidiary of Xstelos Holdings, Inc. (OTC Pink Sheets: XTLS.PK).

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which discuss matters that are not facts, and may include words to indicate their uncertain nature such as "believe," "expect," anticipate," "intend," "plan," "should," "could," "estimate," "project," "will," and "target." Our forward-looking statements convey management's expectations, beliefs, plans and objectives regarding future performance of Auxilium and are based upon preliminary information and management assumptions. No specific assurances can be given with respect to: whether Auxilium will succeed in its efforts in defense of the patents covering Testim, including enforcement of its intellectual property rights and approved labeling, whether Watson will be subject to a 30-month stay of its efforts to launch a generic competitor to Testim, the timing of any such launch by Watson or the expected duration of any patent covering Testim. While the Company may elect to update the forward-looking statements made in this news release in the future, the Company specifically disclaims any obligation to do so. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, intellectual property rights, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration, and those risks discussed in our reports on file with the Securities and Exchange Commission (the "SEC"). Our SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "For Investors - SEC Filings." There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

FCB SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on FCB's parent companies' current estimates and assumptions and, as such, involve uncertainty and risk. Forward-looking statements include the information concerning FCB and its parent companies' possible or assumed future results of operations and also include those preceded or followed by the words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "should," "plans," "targets" and/or similar expressions. These statements relate to future events or future financial performance and involve known and unknown risks, uncertainties and other factors that could cause FCB or its parent companies' actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others, competition from existing products or new products that may emerge, regulatory difficulties relating to products that have already received regulatory approval, potential product liability claims, dependency on third-party manufacturers to supply or manufacture products, ability to establish or maintain collaborations, licensing or other arrangements, Xstelos' ability and third parties' abilities to protect intellectual property rights, limitation on the ability to utilize net operating losses, compliance with obligations under intellectual property licenses with third parties, ability to successfully invest for future growth, and those risks discussed in Xstelos' reports on file with the SEC. The forward-looking statements are not guarantees of future performance, events or circumstances, and actual results may differ materially from those contemplated by these forward-looking statements. For these reasons, one should not place undue reliance on any forward-looking statements. Xstelos' SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov.

Auxilium Contacts:
James E. Fickenscher / CFO	William Q. Sargent, Jr. / V.P., IR
Auxilium Pharmaceuticals, Inc.	Auxilium Pharmaceuticals, Inc.
(484) 321-5900	(484) 321-5900
jfickenscher@auxilium.com	wsargent@auxilium.com

FCB Contacts:
Jonathan M. Couchman, President
FCB I LLC
(603) 658-6100 x502

SOURCE Auxilium Pharmaceuticals, Inc.

New Zoning to Highlight High-Growth Sectors at China Pharma Events

Wed, 23 May 2012 22:40:28 +0000

New Zoning to Highlight High-Growth Sectors at China Pharma Events

PR Newswire

AMSTERDAM, May 23, 2012 /PRNewswire/ -- Leading events organiser UBM Live today announced details of its annual schedule of China events for the global pharmaceutical market. Set to be hosted from 26th to 28th June at the SNIEC in Shanghai, CPhI China for pharmaceutical ingredients, and ICSE China for contract and outsourced services, will be co-located with BioPh China for the biopharmaceutical sector, InnoPack China for innovative packaging services and solutions, and LABWorld China for laboratory and analytical equipment needs. The combined events are expected to host more than 27,000 attendees and 1,700 diverse exhibitors. Attendees of the 2012 China Pharma Portfolio of events will also be able to take advantage of the introduction of zoning, designed to highlight high-growth sectors within the Chinese market and facilitate easier navigation of the events for maximised visitor ROI.

"The size and synergies of CPhI China, ICSE China and the co-located events create a dedicated marketplace for companies to find products and services, including standard and custom APIs. In the Asian pharma market, an increased emphasis has been placed on producing high quality drugs faster as many blockbuster drug patents expire. There is a large interest in generics and biosimilars, as the market demands better versions of drugs at a cheaper price. Statistics have shown that the Chinese market could double as the country improves its health care systems and regulations and IMS Health projected that drug revenue in China would grow by $40 billion through 2013(1)," UBM Brand Director, Haf Cennydd noted. "Active Pharmaceutical Ingredients (APIs) make up more than 50% of the export value of China's pharmaceutical trade and is it estimated that the Chinese market for APIs will witness a compound growth rate of 18% from 2010 to 2017(2). In this flourishing environment CPhI China, ICSE China and co-located events are the only events of their kind that can offer direct access to so many sectors of the Chinese pharmaceutical industry."

Successfully introduced at the CPhI Worldwide events, the new zoning format aims to increase visitor ROI while onsite and supports the goal of more time spent meeting with colleagues and less time spent navigating the exhibition halls. Within the events, there are zones targeted towards specific products and services which will make contacts easier to find the first time. CPhI China will feature new zones for general ingredients, APIs, intermediates, fine chemicals, and natural extracts. ICSE China will be split between contract services and outsourcing, while BioPh China will remain dedicated to biopharmaceuticals only. Co-located event, P-MEC China, will feature a general zone, as well as one for machinery and equipment and one for environment protection and clean technology.

A modular conference programme featuring six bookable sessions will highlight the drivers of the current economy and how to navigate the market as it changes. The specific module topics include pharmaceutical manufacturing, commercializing R&D, export strategies and regulations, developing biosimilars, API sourcing, and delivering re-innovated generics. The modules will be structured over day one and day two, and will be presented by high level speakers from the FDA in China, and leading multi-nationals including Pfizer, Boehringer-Ingelheim, Novartis, and GSK China.

As the Chinese government and Ministry of Health (MoH) continue to upgrade protocols in the pharma market and roll out new plans, companies will need to remain flexible to find success. The recent 12th edition of China's Five-year Plan (for years 2011 to 2015) will also help to serve as a guide for companies to strengthen the national drug distribution industry through active support of acquisitions, mergers and reorganizations, as well as the formulation of competitive strategies for the future. The combined China pharma events provide visitors with a unique opportunity to network directly with key decision makers in the Asian pharmaceutical industry through both existing and new contacts. CPhI China, ICSE China and co-located shows provide a one stop location for sourcing quality pharmaceutical products and services at a reasonable price. The events also provide attendees a direct view into the newest market trends and opportunities which results in increased connections and ROI. To learn more about CPhI China, ICSE China and co-located events, or to register to attend, please visit www.cphi-china.com.

The UBM Live annual schedule of Pharmaceutical events also includes ICSE USA (22-23 May, 2012 at the Pennsylvania Convention Centre in Philadelphia, PA), CPhI, ICSE and BioPh South America (21-23 August, 2012 at the Transamerica Expo Center in Sao Paulo, Brazil), CPhI Worldwide, ICSE, P-MEC and InnoPack (9-11 October, 2012 at the Feria de Madrid, Spain), CPhI and P-MEC India (21-23 November, 2012 at the Bombay Exhibition Centre in Mumbai), CPhI, ICSE, P-MEC and Pharmatec Japan (24-26 April, 2013 at the Tokyo Big Sight Exhibition Centre in Japan) and CPhI South East Asia (20-23 May, 2013 at the Jakarta International Expo in Indonesia).

Sources:
(1) Manufacturing.net: "China could be 3rd largest pharma market by 2011"
(2) CHEManager Europe: "APIs in China: Pharma Industry Booming in Asia"

Notes for Editors:

UBM Live is a division of UBM Plc (LSE: UBM) a leading provider of business information services to the maritime, travel, fashion, technology, healthcare, media, and property industries. UBM offers services in trade shows, online, news distribution, and publishing to customers across the globe. Its brands are represented in more than 30 countries and are organized into specialist teams that serve their business communities helping them excel in their market by working effectively and efficiently. For more information, go to www.ubmlive.com.

New Zoning to Highlight High-Growth Sectors at China Pharma Events

Wed, 23 May 2012 21:53:33 +0000

New Zoning to Highlight High-Growth Sectors at China Pharma Events

PR Newswire

Sources:
(1) Manufacturing.net: "China could be 3rd largest pharma market by 2011"
(2) CHEManager Europe: "APIs in China: Pharma Industry Booming in Asia"

Notes for Editors:

SOURCE UBM Live

Antibody Drugs: Technologies and Global Markets

Wed, 23 May 2012 11:04:07 +0000

Antibody Drugs: Technologies and Global Markets

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibody Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0801344/Antibody-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide a range of information—from detailed analysis through industry trends—to quantify and qualify the rapidly growing market for therapeutic monoclonal antibody (mAb) drugs. Forecasts and trends are gleaned from industry sources, analyst reports, and company forecasts, as well as from assessment of available and emerging technologies.

The report develops forecasts for sales of the mAb market by individual antibody, by therapeutic antibody target (epidermal growth factor receptor [EGFR], cluster of differentiation [CD] 20, tumor necrosis factor [TNF] alpha, etc.), and by major disease applications from 2011 through 2016. Additionally, we examine strategies employed by biopharmaceutical firms to develop and market products in this explosive market sector.

Our main objective is to present a comprehensive analysis of the current market for therapeutic mAb disease-modifying products and to forecast this market's future direction through 2016.

REASONS FOR DOING THE STUDY

Therapeutic mAbs represent the largest and one of the fastest-growing classes of biopharmaceutical products by sales in the U.S. and throughout the world. Of the top 20 drugs by sales throughout the world today, five are mAbs.

During our forecast period from 2011 through 2016, eight new mAbs are forecast to enter the market, and sales of therapeutic mAbs are estimated to grow from approximately $43 billion in 2010 to nearly $58 billion in 2016. Sales of humanized and fully human antibodies for autoimmune/inflammatory diseases such as rheumatoid arthritis, ulcerative colitis, and multiple sclerosis are forecast to experience the fastest sales growth.

This period of dynamic growth for humanized and fully human antibodies plus the continued rollout of antibody-drug conjugates (ADCs), also called immunoconjugates, is expected to result in stagnating sales of chimeric antibodies from 2011 through 2016.

INTENDED AUDIENCE

This study will be of interest to those working in the biotechnology and pharmaceutical industries and related life science, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug research.

Both individuals looking for a comprehensive listing of mAbs in human clinical-stage development and individuals looking at how the mAb drug marketplace is expected to change (in terms of sales and technology) in the coming years will find this report extremely useful.

SCOPE OF REPORT

This report analyzes and assesses therapeutic applications of mAbs in human medicine. Covered in this report are mAbs exclusively, including the combination of mAbs when they are attached to a cytotoxic agent such as with ADCs.

Excluded from this report are diagnostic uses of mAbs (such as for imaging purposes) and therapeutic antibodies for veterinary use. Also excluded are research applications of mAbs.

The scope of the study is global. The "Overview" section provides a discussion of the importance and advantages of antibody-based products, valuation of antibody product sales, patent issues and differences in applicability of mAbs products versus polyclonal antibodies (pAbs), and other competing agents such as small molecule therapeutics.

The "Technology and Technical Issues" section discusses new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches—in particular transgenic sources—of antibody production.

The "Products" section provides a synopsis of more than 60 mAb drugs, including those currently marketed and those in late-stage development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, sales by target and technology (for mAb-based drugs), as well as global market size and growth estimates for therapeutic mAbs.

The "Applications" section provides an overview of the leading indications for available and emerging antibody-based therapeutics. These include selected indications for autoimmune diseases (specifically rheumatoid arthritis, psoriasis, and Crohn's disease), cancer indications (specifically the most common solid tumor types, leukemias, and lymphomas) cardiovascular diseases, infectious diseases, ophthalmic indications, and respiratory diseases.

The "Industry Structure" section provides an overview of the antibody industry as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.

The "Company Profiles" section emphasizes companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

INFORMATION SOURCES

The information in this report was derived from the review of more than 200 biotechnology and pharmaceutical companies developing mAbs and the review of journal articles related to mAb therapeutics. Sources of information include PubMed, ClinicalTrials.gov, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA), and company presentations and annual reports.

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES . 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

INFORMATION SOURCES . 3

ANALYST CREDENTIALS 3

RELATED REPORTS . 3

BCC ON-LINE SERVICES . 4

DISCLAIMER . 4

CHAPTER TWO: SUMMARY 5

SUMMARY TABLE GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2016 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016 ($ MILLIONS) . 6

CHAPTER THREE: OVERVIEW 7

DEFINITIONS 7

DEFINITIONS (CONTINUED) . 8

THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS . 9

THE IMPORTANCE OF ANTIBODY … (CONTINUED) 10

INTELLECTUAL PROPERTY ISSUES AND PATENT LICENSING 11

THE HISTORY OF THE COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS . 11

TABLE 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS . 11

ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS 12

WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS COMPARED WITH POLYCLONAL ANTIBODY PRODUCTS? 13

VALUATION OF ANTIBODY PRODUCT SALES . 14

CHAPTER FOUR: TECHNOLOGY AND TECHNICAL ISSUES . 15

OVERVIEW . 15

OVERVIEW (CONTINUED) . 16

TABLE 2 MONOCLONAL ANTIBODIES VERSUS SMALL MOLECULE DRUGS . 17

TABLE 2 (CONTINUED) . 18

TABLE 3 MONOCLONAL ANTIBODIES VERSUS POLYCLONAL ANTIBODIES . 18

THE HAMA PROBLEM AND ITS RESOLUTION . 19

PHAGE DISPLAY AND POLYSOME DISPLAY 20

PHAGE DISPLAY AND POLYSOME … (CONTINUED) 21

DIRECTED EVOLUTION 22

ANTIBODY CLASSES 22

TABLE 4 ANTIBODY TYPES AND DESCRIPTIONS . 23

ANTIBODY FORMS IN PRODUCTS 23

TABLE 5 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES BY ANTIBODY TECHNOLOGY TYPE, THROUGH 2016 ($ MILLIONS) . 24

TABLE 6 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY

ANTIBODY FORM (NUMBER/%) 25

TABLE 7 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TECHNOLOGY FORM AND STAGE OF DEVELOPMENT 25

TABLE 8 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TARGET . 26

ABTIDES 26

ANTIBODY-DRUG CONJUGATES / IMMUNOCONJUGATES 26

ANTISERUMS . 27

BISPECIFIC ANTIBODIES 28

CAMOUFLAGED ANTIBODIES 28

CHIMERIC ANTIBODIES 29

HUMANIZED ANTIBODIES 29

Humanized Antibodies (Continued) . 30

FULLY HUMAN ANTIBODIES 31

PROGENITOR STEM CELLS . 32

SINGLE-CHAIN ANTIBODIES 32

SYNTHETIC ANTIBODIES 33

SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET 34

TABLE 9 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES 34

TABLE 9 (CONTINUED) . 35

TABLE 9 (CONTINUED) . 36

THE SPECIAL CASE OF ENBREL. 36

ANTIBODY TECHNOLOGIES IN DEVELOPMENT 37

AFFIBODIES . 37

DOMAIN ANTIBODIES 37

NANOBODIES . 38

TABLE 10 MONOCLONAL ANTIBODIES IN PHASE 3 DEVELOPMENT 39

TABLE 10 (CONTINUED) . 40

TABLE 11 MONOCLONAL ANTIBODIES IN PHASE 2 DEVELOPMENT 40

TABLE 11 (CONTINUED) . 41

TABLE 11 (CONTINUED) . 42

TABLE 11 (CONTINUED) . 43

TABLE 11 (CONTINUED) . 44

TABLE 11 (CONTINUED) . 45

TABLE 11 (CONTINUED) . 46

TABLE 11 (CONTINUED) 47

TABLE 12 MONOCLONAL ANTIBODIES IN PHASE 1 DEVELOPMENT 47

TABLE 12 (CONTINUED) 48

TABLE 12 (CONTINUED) . 49

TABLE 12 (CONTINUED) . 50

TABLE 12 (CONTINUED) . 51

TABLE 12 (CONTINUED) . 52

NEW DIRECTIONS IN ANTIBODY RESEARCH 53

THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS 53

THE MARKET OPPORTUNITY FOR …(CONTINUED) 54

THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS . 55

THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS 56

THE TRANSGENIC ADVANTAGE . 56

TRADITIONAL PRODUCTION METHODS 57

MICROBIAL FERMENTATION . 58

MAMMALIAN CELL CULTURE 58

THE ENBREL SHORTAGE . 59

THE CRUNCH IN CAPACITY. 59

REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION 60

GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS 61

PRODUCTION OF ANTIBODIES IN ANIMALS . 62

PRODUCTION OF ANTIBODIES … (CONTINUED) . 63

GOATS AS MONOCLONAL ANTIBODIES FACTORIES 64

PRODUCTION OF ANTIBODIES IN PLANTS 64

PLASTIDS 64

TARGETING AND COMPARTMENTALIZING 65

TRANSGENIC SEEDS FOR ANTIBODY STORAGE 65

CHAPTER FIVE: PRODUCTS 66

OVERVIEW . 66

MARKETED PRODUCTS 66

TABLE 13 GLOBAL SALES OF MONOCLONAL ANTIBODIES, BY

PRODUCT THROUGH 2016 ($ MILLIONS) . 67

TABLE 14 U.S. SALES OF MONOCLONAL ANTIBODIES, BY

PRODUCT THROUGH 2016 ($ MILLIONS) . 68

TABLE 15 REST OF WORLD SALES OF MONOCLONAL ANTIBODIES, BY PRODUCT THROUGH 2016 ($ MILLIONS) . 69

GEMTUZUMAB OZOGAMICIN (MYLOTARG) 70

DACLIZUMAB (ZENAPAX) 71

Daclizumab (Zenapax) (Continued) 72

TABLE 16 DACLIZUMAB CHOICE STUDY RESULTS . 73

CATUMAXOMAB (REMOVAB) 74

TOCILIZUMAB (ACTEMRA, ROACTEMRA, RG1569) . 75

TRASTUZUMAB (HERCEPTIN, RG597) . 76

Trastuzumab (Herceptin, RG597) (Continued) 77

BEVACLIZUMAB (AVASTIN, RG435) . 78

Bevaclizumab (Avastin, RG435) (Continued) 79

Bevaclizumab (Avastin, RG435) (Continued) 80

CETUXIMAB (ERBITUX) . 81

Cetuximab (Erbitux) (Continued) . 82

PANITUMUMAB (VECTIBIX) 83

Panitumumab (Vectibix) (Continued) . 84

IBRITUMOMAB TIUXETAN (ZEVALIN) 85

Results of Trials . 86

Sales of Zevalin 87

ALEMTUZUMAB (LEMTRADA, CAMPATH, MABCAMPATH) 88

Alemtuzumab (… (Continued) 89

Alemtuzumab (… (Continued) 90

NATALIZUMAB (TYSABRI) . 91

TABLE 17 TYSABRI SENTINEL AND AFFIRM STUDY RESULTS 92

Natalizumab (Tysabri) (Continued) 93

TOSITUMOMAB-I (BEXXAR) 94

Tositumomab-I (Bexxar) (Continued) . 95

OFATUMUMAB (ARZERRA) 96

Ofatumumab (Arzerra) (Continued) . 97

RITUXIMAB (RITUXAN, MABTHERA, RG105) . 98

INFLIXIMAB (REMICADE) 99

Infliximab (Remicade) (Continued) . 100

DENOSUMAB (PROLIA, XGEVA) . 101

IPILIMUMAB (YERVOY, MDX-010) 102

ADALIMUMAB (HUMIRA) . 103

GOLIMUMAB (SIMPONI) 104

CANAKINUMAB (ILARIS, ACZ885) 105

ECULIZUMAB (SOLIRIS) . 106

PALIVIZUMAB (SYNAGIS) 107

ABCIXIMAB (REOPRO) 108

Abciximab (ReoPro) (Continued) . 109

Abciximab (ReoPro) (Continued) . 110

RANIBIZUMAB (LUCENTIS) . 111

Ranibizumab (Lucentis) (Continued) 112

MUROMONAB (ORTHOCLONE OKT3) 113

OMALIZUMAB (XOLAIR) . 113

USTEKINUMAB (STELARA, CNTO 1275) 114

Ustekinumab (Stelara, CNTO 1275) (Continued) 115

CERTOLIZUMAB PEGOL (CIMZIA) . 116

BASILIXIMAB (SIMULECT) 116

Basiliximab (Simulect) (Continued) 117

BELIMUMAB (BENLYSTA) . 118

NIMOTUZUMAB . 119

PRODUCTS IN DEVELOPMENT . 119

TANEZUMAB (RN624) 119

VEDOLIZUMAB (MLN0002). 120

LY2127399 121

OTELIXIZUMAB . 121

MEPOLIZUMAB (BOSATRIA) 122

TEPLIZUMAB (MGA031, HOKT3-GAMMA1) . 122

BAPINEUZUMAB (AAB-001) . 123

GANITUMAB (AMG 479) 124

OBINUTUZUMAB (AFUTUZUMAB, GA101, RG7159) 125

ZANOLIMUMAB (FORMERLY HUMAX-CD4) . 126

RESLIZUMAB (CINQUIL) 127

BLINATUMOMAB (MT103) 128

FARLETUZUMAB (MORAB-003) . 128

EPRATUZUMAB 129

GIRENTUXIMAB (RENCAREX) 129

INOTUZUMAB OZOGAMICIN (CMC-544) 130

BRIAKINUMAB (ABT-874) . 131

ELOTUZUMAB 132

SILTUXIMAB (CNTO 328) 133

TRASTUZUMAB EMTANSINE (T-DM1, RG3502) 133

INOLIMOMAB (LEUKOTAC) . 134

ITOLIZUMAB (T1H, ANTI-CD6) 134

NAPTUMOMAB ESTAFENATOX (ANYARA) . 135

NECITUMUMAB (IMC-11F8) . 135

PERTUZUMAB 136

RAMUCIRUMAB (IMC-1121B, LY3009806) 137

RAXIBACUMAB 138

MK-3415, MK-6072, AND MK-3415A . 138

MK-3415, MK-6072, and MK-3415A (Continued) 139

CHAPTER SIX: APPLICATIONS 140

OVERVIEW . 140

TABLE 18 MONOCLONAL ANTIBODIES ON THE MARKET, BY

INDICATION 2011 (NUMBER/%) 140

TABLE 19 GLOBAL SALES OF THERAPEUTIC MONOCLONAL

ANTIBODIES, BY APPLICATION, THROUGH 2016 ($ MILLIONS) . 141

TABLE 20 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT, BY INDICATION, 2011 (NUMBER/%) . 141

TABLE 20 (CONTINUED) . 142

AUTOIMMUNE DISEASES 142

CROHN'S DISEASE 143

PSORIASIS . 144

RHEUMATOID ARTHRITIS . 145

TABLE 21 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFLAMMATORY DISEASES (NOT INCLUDING MS), THROUGH 2016 ($ MILLIONS) . 145

SOLID TUMORS 146

U.S. CANCER STATISTICS 146

TABLE 22 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2011 . 147

TABLE 23 CANCER PREVALENCE RATES IN THE U.S., 2008 (IN THOUSANDS) . 148

BREAST CANCER . 149

COLORECTAL CANCER 149

HEAD AND NECK CANCER 149

KIDNEY CANCER . 149

LIVER CANCER 149

LUNG CANCER . 150

MALIGNANT MELANOMA 150

OSTEOSARCOMA . 151

OVARIAN CANCER 151

PANCREATIC CANCER . 152

PROSTATE CANCER 152

STOMACH CANCER . 153

ANTIBODY PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER . 153

TABLE 24 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF SOLID TUMORS, BY REGION, THROUGH 2016 ($ MILLIONS) . 153

LYMPHOMAS AND LEUKEMIAS 153

NON-HODGKIN LYMPHOMA . 154

LEUKEMIAS 154

Leukemias (Continued) . 155

CARDIOVASCULAR DISEASES 156

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY 157

INFECTIOUS DISEASES 158

CYTOMEGALOVIRUS INFECTION 159

HEPATITIS 160

RESPIRATORY SYNCYTIAL VIRUS INFECTION 160

TABLE 25 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF INFECTIOUS DISEASES, BY REGION, THROUGH 2016 ($ MILLIONS) . 161

MULTIPLE SCLEROSIS . 161

TABLE 26 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS, BY REGION, THROUGH 2016 ($ MILLIONS) . 162

OPHTHALMIC DISEASES 162

MACULAR DEGENERATION 162

OTHER THERAPEUTIC APPLICATIONS . 163

TABLE 27 SALES OF MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF OTHER DISEASES, BY REGION, THROUGH 2016 ($ MILLIONS) . 163

CHAPTER SEVEN: INDUSTRY STRUCTURE . 164

OVERVIEW . 164

ORIGINATORS . 164

COMMERCIAL DEVELOPERS . 165

VENDORS . 166

MANUFACTURERS . 166

TECHNOLOGY INNOVATORS. 167

PRICING FORECASTS 168

THE REGULATORY ENVIRONMENT 168

THE REGULATORY ENVIRONMENT (CONTINUED) . 169

GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS . 170

GENOMICS AND MONOCLONAL … (CONTINUED) . 171

GENOMICS AND MONOCLONAL … (CONTINUED) . 172

COMPANY SALES AND MARKET SHARE . 173

TABLE 28 SALES OF MARKETED ANTIBODIES BY

MANUFACTURER, THROUGH 2016 ($ MILLIONS) 174

TABLE 29 MANUFACTURERS OF ANTIBODIES BY MARKET SHARE, 2011 AND 2016 (%) 175

TABLE 30 MONOCLONAL ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY COMPANY . 176

COMPANY PROFILES 176

ABBOTT LABORATORIES . 176

ALEXION PHARMACEUTICALS 177

AMGEN 178

ASTRAZENECA . 179

AstraZeneca – U.S. Headquarters 179

BAYER AG . 180

Bayer (U.S. Location) 180

BIOGEN IDEC . 181

BRISTOL-MYERS SQUIBB 182

BTG . 183

DAIICHI SANKYO . 183

ELAN 184

EMERGENT BIOSOLUTIONS . 185

EISAI 185

ELI LILLY 186

GENMAB 186

Genmab (U.S. Location) 187

GLAXOSMITHKLINE . 187

GlaxoSmithKline (U.S. Location) 187

HUMAN GENOME SCIENCES 188

JOHNSON & JOHNSON . 188

KALOBIOS PHARMACEUTICALS 189

MERCK KGAA (MERCK SERONO) . 190

MORPHOSYS . 191

NOVARTIS . 191

PFIZER . 192

ROCHE . 193

To order this report:Biopharmaceutical Industry: Antibody Drugs: Technologies and Global Markets

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Wed, 23 May 2012 10:41:31 +0000

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

http://www.reportlinker.com/p0191857/Pharmaceuticals---Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu

Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The G8 countries contributed $510,182.1 million in 2010 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.9% between 2006 and 2010.

The G8 countries are expected to reach a value of $629,493.5 million in 2015, with a CAGR of 4.3% over the 2010–15 period.Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 52.1% in 2010.

Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $265,735.9 million in 2010.

The US is expected to lead the Pharmaceuticals industry in the G8 nations with a value of $346,744.2 million in 2015.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs for in-patient and out-patient usage, valued at ex-manufacturer prices.

Any currency conversions used within this report have been calculated using 2010 constant exchange rates.

TABLE OF CONTENTSINTRODUCTION 16What is this report about? 16Who is the target reader? 16Market definition 16GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK 17PHARMACEUTICALS IN CANADA 24Market overview 24Market value 25Market segmentation 26Market share 27Five forces analysis 28Leading companies 39Market forecasts 50Macroeconomic indicators 51PHARMACEUTICALS IN FRANCE 53Market overview 53Market value 54Market segmentation 55Market share 56Five forces analysis 57Leading companies 68Market forecasts 80Macroeconomic indicators 81PHARMACEUTICALS IN GERMANY 83Market overview 83Market value 84Market segmentation 85Market share 86Five forces analysis 87Leading companies 98Market forecasts 110Macroeconomic indicators 111PHARMACEUTICALS IN ITALY 113Market overview 113Market value 114Market segmentation 115Market share 116Five forces analysis 117Leading companies 128Market forecasts 141Macroeconomic indicators 142PHARMACEUTICALS IN JAPAN 144Market overview 144Market value 145Market segmentation 146Market share 147Five forces analysis 148Leading companies 159Market forecasts 170Macroeconomic indicators 171PHARMACEUTICALS IN RUSSIA 173Market overview 173Market value 174Market segmentation 175Market share 176Five forces analysis 177Leading companies 189Market forecasts 200Macroeconomic indicators 201PHARMACEUTICALS IN THE UNITED KINGDOM 203Market overview 203Market value 204Market segmentation 205Market share 206Five forces analysis 207Leading companies 219Market forecasts 231Macroeconomic indicators 232PHARMACEUTICALS IN THE UNITED STATES 234Market overview 234Market value 235Market segmentation 236Market share 237Five forces analysis 238Leading companies 249Market forecasts 265Macroeconomic indicators 266APPENDIX 268Data Research Methodology 268About Datamonitor 269Disclaimer 269

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($m), 2006–15 18

Table 2: G8 pharmaceuticals industry, revenue by country ($m), 2006–10 21

Table 3: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 23

Table 4: Canada pharmaceuticals market value: $ million, 2006–10 25

Table 5: Canada pharmaceuticals market segmentation: % share, by value, 2010 26

Table 6: Canada pharmaceuticals market share: % share, by value, 2010 27

Table 7: AstraZeneca PLC: key facts 39

Table 8: AstraZeneca PLC: key financials ($) 41

Table 9: AstraZeneca PLC: key financial ratios 41

Table 10: Johnson & Johnson: key facts 43

Table 11: Johnson & Johnson: key financials ($) 44

Table 12: Johnson & Johnson: key financial ratios 45

Table 13: Pfizer Inc.: key facts 47

Table 14: Pfizer Inc.: key financials ($) 48

Table 15: Pfizer Inc.: key financial ratios 48

Table 16: Canada pharmaceuticals market value forecast: $ million, 2010–15 50

Table 17: Canada size of population (million), 2006–10 51

Table 18: Canada gdp (constant 2000 prices, $ billion), 2006–10 51

Table 19: Canada gdp (current prices, $ billion), 2006–10 51

Table 20: Canada inflation, 2006–10 52

Table 21: Canada consumer price index (absolute), 2006–10 52

Table 22: Canada exchange rate, 2006–10 52

Table 23: France pharmaceuticals market value: $ million, 2006–10 54

Table 24: France pharmaceuticals market segmentation: % share, by value, 2010 55

Table 25: France pharmaceuticals market share: % share, by value, 2010 56

Table 26: AstraZeneca PLC: key facts 68

Table 27: AstraZeneca PLC: key financials ($) 70

Table 28: AstraZeneca PLC: key financial ratios 70

Table 29: GlaxoSmithKline Plc: key facts 72

Table 30: GlaxoSmithKline Plc: key financials ($) 74

Table 31: GlaxoSmithKline Plc: key financials (£) 75

Table 32: GlaxoSmithKline Plc: key financial ratios 75

Table 33: Pfizer Inc.: key facts 77

Table 34: Pfizer Inc.: key financials ($) 78

Table 35: Pfizer Inc.: key financial ratios 78

Table 36: France pharmaceuticals market value forecast: $ million, 2010–15 80

Table 37: France size of population (million), 2006–10 81

Table 38: France gdp (constant 2000 prices, $ billion), 2006–10 81

Table 39: France gdp (current prices, $ billion), 2006–10 81

Table 40: France inflation, 2006–10 82

Table 41: France consumer price index (absolute), 2006–10 82

Table 42: France exchange rate, 2006–10 82

Table 43: Germany pharmaceuticals market value: $ million, 2006–10 84

Table 44: Germany pharmaceuticals market segmentation: % share, by value, 2010 85

Table 45: Germany pharmaceuticals market share: % share, by value, 2010 86

Table 46: GlaxoSmithKline Plc: key facts 98

Table 47: GlaxoSmithKline Plc: key financials ($) 100

Table 48: GlaxoSmithKline Plc: key financials (£) 101

Table 49: GlaxoSmithKline Plc: key financial ratios 101

Table 50: Novartis AG: key facts 103

Table 51: Novartis AG: key financials ($) 104

Table 52: Novartis AG: key financial ratios 105

Table 53: Pfizer Inc.: key facts 107

Table 54: Pfizer Inc.: key financials ($) 108

Table 55: Pfizer Inc.: key financial ratios 108

Table 56: Germany pharmaceuticals market value forecast: $ million, 2010–15 110

Table 57: Germany size of population (million), 2006–10 111

Table 58: Germany gdp (constant 2000 prices, $ billion), 2006–10 111

Table 59: Germany gdp (current prices, $ billion), 2006–10 111

Table 60: Germany inflation, 2006–10 112

Table 61: Germany consumer price index (absolute), 2006–10 112

Table 62: Germany exchange rate, 2006–10 112

Table 63: Italy pharmaceuticals market value: $ million, 2006–10 114

Table 64: Italy pharmaceuticals market segmentation: % share, by value, 2010 115

Table 65: Italy pharmaceuticals market share: % share, by value, 2010 116

Table 66: Chiesi Farmaceutici SpA: key facts 128

Table 67: GlaxoSmithKline Plc: key facts 131

Table 68: GlaxoSmithKline Plc: key financials ($) 133

Table 69: GlaxoSmithKline Plc: key financials (£) 134

Table 70: GlaxoSmithKline Plc: key financial ratios 134

Table 71: Menarini Group, The: key facts 136

Table 72: Pfizer Inc.: key facts 138

Table 73: Pfizer Inc.: key financials ($) 139

Table 74: Pfizer Inc.: key financial ratios 139

Table 75: Italy pharmaceuticals market value forecast: $ million, 2010–15 141

Table 76: Italy size of population (million), 2006–10 142

Table 77: Italy gdp (constant 2000 prices, $ billion), 2006–10 142

Table 78: Italy gdp (current prices, $ billion), 2006–10 142

Table 79: Italy inflation, 2006–10 143

Table 80: Italy consumer price index (absolute), 2006–10 143

Table 81: Italy exchange rate, 2006–10 143

Table 82: Japan pharmaceuticals market value: $ million, 2006–10 145

Table 83: Japan pharmaceuticals market segmentation: % share, by value, 2010 146

Table 84: Japan pharmaceuticals market share: % share, by value, 2010 147

Table 85: Astellas: key facts 159

Table 86: Astellas: key financials ($) 160

Table 87: Astellas: key financials (¥) 161

Table 88: Astellas: key financial ratios 161

Table 89: Daiichi Sankyo Co., Ltd.: key facts 163

Table 90: Daiichi Sankyo Co., Ltd.: key financials ($) 164

Table 91: Daiichi Sankyo Co., Ltd.: key financials (¥) 164

Table 92: Daiichi Sankyo Co., Ltd.: key financial ratios 165

Table 93: Pfizer Inc.: key facts 167

Table 94: Pfizer Inc.: key financials ($) 168

Table 95: Pfizer Inc.: key financial ratios 168

Table 96: Japan pharmaceuticals market value forecast: $ million, 2010–15 170

Table 97: Japan size of population (million), 2006–10 171

Table 98: Japan gdp (constant 2000 prices, $ billion), 2006–10 171

Table 99: Japan gdp (current prices, $ billion), 2006–10 171

Table 100: Japan inflation, 2006–10 172

Table 101: Japan consumer price index (absolute), 2006–10 172

Table 102: Japan exchange rate, 2006–10 172

Table 103: Russia pharmaceuticals market value: $ million, 2006–10 174

Table 104: Russia pharmaceuticals market segmentation: % share, by value, 2010 175

Table 105: Russia pharmaceuticals market share: % share, by value, 2010 176

Table 106: Novartis AG: key facts 189

Table 107: Novartis AG: key financials ($) 190

Table 108: Novartis AG: key financial ratios 191

Table 109: Pharmstandard OJSC: key facts 193

Table 110: Pharmstandard OJSC: key financials ($) 194

Table 111: Pharmstandard OJSC: key financials (RUB) 194

Table 112: Pharmstandard OJSC: key financial ratios 194

Table 113: Sanofi-Aventis SA: key facts 196

Table 114: Sanofi-Aventis SA: key financials ($) 197

Table 115: Sanofi-Aventis SA: key financials (€) 197

Table 116: Sanofi-Aventis SA: key financial ratios 198

Table 117: Russia pharmaceuticals market value forecast: $ million, 2010–15 200

Table 118: Russia size of population (million), 2006–10 201

Table 119: Russia gdp (constant 2000 prices, $ billion), 2006–10 201

Table 120: Russia gdp (current prices, $ billion), 2006–10 201

Table 121: Russia inflation, 2006–10 202

Table 122: Russia consumer price index (absolute), 2006–10 202

Table 123: Russia exchange rate, 2006–10 202

Table 124: United Kingdom pharmaceuticals market value: $ million, 2006–10 204

Table 125: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205

Table 126: United Kingdom pharmaceuticals market share: % share, by value, 2010 206

Table 127: AstraZeneca PLC: key facts 219

Table 128: AstraZeneca PLC: key financials ($) 221

Table 129: AstraZeneca PLC: key financial ratios 221

Table 130: GlaxoSmithKline Plc: key facts 223

Table 131: GlaxoSmithKline Plc: key financials ($) 225

Table 132: GlaxoSmithKline Plc: key financials (£) 226

Table 133: GlaxoSmithKline Plc: key financial ratios 226

Table 134: Pfizer Inc.: key facts 228

Table 135: Pfizer Inc.: key financials ($) 229

Table 136: Pfizer Inc.: key financial ratios 229

Table 137: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231

Table 138: United Kingdom size of population (million), 2006–10 232

Table 139: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10 232

Table 140: United Kingdom gdp (current prices, $ billion), 2006–10 232

Table 141: United Kingdom inflation, 2006–10 233

Table 142: United Kingdom consumer price index (absolute), 2006–10 233

Table 143: United Kingdom exchange rate, 2006–10 233

Table 144: United States pharmaceuticals market value: $ million, 2006–10 235

Table 145: United States pharmaceuticals market segmentation: % share, by value, 2010 236

Table 146: United States pharmaceuticals market share: % share, by value, 2010 237

Table 147: GlaxoSmithKline Plc: key facts 249

Table 148: GlaxoSmithKline Plc: key financials ($) 251

Table 149: GlaxoSmithKline Plc: key financials (£) 252

Table 150: GlaxoSmithKline Plc: key financial ratios 252

Table 151: Johnson & Johnson: key facts 254

Table 152: Johnson & Johnson: key financials ($) 255

Table 153: Johnson & Johnson: key financial ratios 256

Table 154: Merck & Co., Inc.: key facts 258

Table 155: Merck & Co., Inc.: key financials ($) 259

Table 156: Merck & Co., Inc.: key financial ratios 260

Table 157: Pfizer Inc.: key facts 262

Table 158: Pfizer Inc.: key financials ($) 263

Table 159: Pfizer Inc.: key financial ratios 263

Table 160: United States pharmaceuticals market value forecast: $ million, 2010–15 265

Table 161: United States size of population (million), 2006–10 266

Table 162: United States gdp (constant 2000 prices, $ billion), 2006–10 266

Table 163: United States gdp (current prices, $ billion), 2006–10 266

Table 164: United States inflation, 2006–10 267

Table 165: United States consumer price index (absolute), 2006–10 267

Table 166: United States exchange rate, 2006–10 267

LIST OF FIGURESFigure 1: G8 pharmaceuticals industry, revenue($m), 2006–15 17Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2010 19Figure 3: G8 pharmaceuticals industry, revenue by country ($m), 2006–10 20Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15 22Figure 5: Canada pharmaceuticals market value: $ million, 2006–10 25Figure 6: Canada pharmaceuticals market segmentation: % share, by value, 2010 26Figure 7: Canada pharmaceuticals market share: % share, by value, 2010 27Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2010 28Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2010 29Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2010 31Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2010 33Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2010 35Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2010 37Figure 14: AstraZeneca PLC: revenues & profitability 42Figure 15: AstraZeneca PLC: assets & liabilities 42Figure 16: Johnson & Johnson: revenues & profitability 45Figure 17: Johnson & Johnson: assets & liabilities 46Figure 18: Pfizer Inc.: revenues & profitability 49Figure 19: Pfizer Inc.: assets & liabilities 49Figure 20: Canada pharmaceuticals market value forecast: $ million, 2010–15 50Figure 21: France pharmaceuticals market value: $ million, 2006–10 54Figure 22: France pharmaceuticals market segmentation: % share, by value, 2010 55Figure 23: France pharmaceuticals market share: % share, by value, 2010 56Figure 24: Forces driving competition in the pharmaceuticals market in France, 2010 57Figure 25: Drivers of buyer power in the pharmaceuticals market in France, 2010 58Figure 26: Drivers of supplier power in the pharmaceuticals market in France, 2010 60Figure 27: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010 62Figure 28: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2010 64Figure 29: Drivers of degree of rivalry in the pharmaceuticals market in France, 2010 66Figure 30: AstraZeneca PLC: revenues & profitability 71Figure 31: AstraZeneca PLC: assets & liabilities 71Figure 32: GlaxoSmithKline Plc: revenues & profitability 76Figure 33: GlaxoSmithKline Plc: assets & liabilities 76Figure 34: Pfizer Inc.: revenues & profitability 79Figure 35: Pfizer Inc.: assets & liabilities 79Figure 36: France pharmaceuticals market value forecast: $ million, 2010–15 80Figure 37: Germany pharmaceuticals market value: $ million, 2006–10 84Figure 38: Germany pharmaceuticals market segmentation: % share, by value, 2010 85Figure 39: Germany pharmaceuticals market share: % share, by value, 2010 86Figure 40: Forces driving competition in the pharmaceuticals market in Germany, 2010 87Figure 41: Drivers of buyer power in the pharmaceuticals market in Germany, 2010 88Figure 42: Drivers of supplier power in the pharmaceuticals market in Germany, 2010 90Figure 43: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2010 92Figure 44: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2010 94Figure 45: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2010 96Figure 46: GlaxoSmithKline Plc: revenues & profitability 102Figure 47: GlaxoSmithKline Plc: assets & liabilities 102Figure 48: Novartis AG: revenues & profitability 105Figure 49: Novartis AG: assets & liabilities 106Figure 50: Pfizer Inc.: revenues & profitability 109Figure 51: Pfizer Inc.: assets & liabilities 109Figure 52: Germany pharmaceuticals market value forecast: $ million, 2010–15 110Figure 53: Italy pharmaceuticals market value: $ million, 2006–10 114Figure 54: Italy pharmaceuticals market segmentation: % share, by value, 2010 115Figure 55: Italy pharmaceuticals market share: % share, by value, 2010 116Figure 56: Forces driving competition in the pharmaceuticals market in Italy, 2010 117Figure 57: Drivers of buyer power in the pharmaceuticals market in Italy, 2010 118Figure 58: Drivers of supplier power in the pharmaceuticals market in Italy, 2010 120Figure 59: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2010 122Figure 60: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2010 124Figure 61: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2010 126Figure 62: GlaxoSmithKline Plc: revenues & profitability 135Figure 63: GlaxoSmithKline Plc: assets & liabilities 135Figure 64: Pfizer Inc.: revenues & profitability 140Figure 65: Pfizer Inc.: assets & liabilities 140Figure 66: Italy pharmaceuticals market value forecast: $ million, 2010–15 141Figure 67: Japan pharmaceuticals market value: $ million, 2006–10 145Figure 68: Japan pharmaceuticals market segmentation: % share, by value, 2010 146Figure 69: Japan pharmaceuticals market share: % share, by value, 2010 147Figure 70: Forces driving competition in the pharmaceuticals market in Japan, 2010 148Figure 71: Drivers of buyer power in the pharmaceuticals market in Japan, 2010 149Figure 72: Drivers of supplier power in the pharmaceuticals market in Japan, 2010 151Figure 73: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2010 153Figure 74: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2010 155Figure 75: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2010 157Figure 76: Astellas: revenues & profitability 162Figure 77: Astellas: assets & liabilities 162Figure 78: Daiichi Sankyo Co., Ltd.: revenues & profitability 165Figure 79: Daiichi Sankyo Co., Ltd.: assets & liabilities 166Figure 80: Pfizer Inc.: revenues & profitability 169Figure 81: Pfizer Inc.: assets & liabilities 169Figure 82: Japan pharmaceuticals market value forecast: $ million, 2010–15 170Figure 83: Russia pharmaceuticals market value: $ million, 2006–10 174Figure 84: Russia pharmaceuticals market segmentation: % share, by value, 2010 175Figure 85: Russia pharmaceuticals market share: % share, by value, 2010 176Figure 86: Forces driving competition in the pharmaceuticals market in Russia, 2010 177Figure 87: Drivers of buyer power in the pharmaceuticals market in Russia, 2010 179Figure 88: Drivers of supplier power in the pharmaceuticals market in Russia, 2010 181Figure 89: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2010 183Figure 90: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2010 185Figure 91: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2010 187Figure 92: Novartis AG: revenues & profitability 191Figure 93: Novartis AG: assets & liabilities 192Figure 94: Pharmstandard OJSC: revenues & profitability 195Figure 95: Sanofi-Aventis SA: revenues & profitability 198Figure 96: Sanofi-Aventis SA: assets & liabilities 199Figure 97: Russia pharmaceuticals market value forecast: $ million, 2010–15 200Figure 98: United Kingdom pharmaceuticals market value: $ million, 2006–10 204Figure 99: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010 205Figure 100: United Kingdom pharmaceuticals market share: % share, by value, 2010 206Figure 101: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2010 207Figure 102: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2010 209Figure 103: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2010 211Figure 104: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2010 213Figure 105: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2010 215Figure 106: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2010 217Figure 107: AstraZeneca PLC: revenues & profitability 222Figure 108: AstraZeneca PLC: assets & liabilities 222Figure 109: GlaxoSmithKline Plc: revenues & profitability 227Figure 110: GlaxoSmithKline Plc: assets & liabilities 227Figure 111: Pfizer Inc.: revenues & profitability 230Figure 112: Pfizer Inc.: assets & liabilities 230Figure 113: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15 231Figure 114: United States pharmaceuticals market value: $ million, 2006–10 235Figure 115: United States pharmaceuticals market segmentation: % share, by value, 2010 236Figure 116: United States pharmaceuticals market share: % share, by value, 2010 237Figure 117: Forces driving competition in the pharmaceuticals market in the United States, 2010 238Figure 118: Drivers of buyer power in the pharmaceuticals market in the United States, 2010 239Figure 119: Drivers of supplier power in the pharmaceuticals market in the United States, 2010 241Figure 120: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2010 243Figure 121: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2010 245Figure 122: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2010 247Figure 123: GlaxoSmithKline Plc: revenues & profitability 253Figure 124: GlaxoSmithKline Plc: assets & liabilities 253Figure 125: Johnson & Johnson: revenues & profitability 256Figure 126: Johnson & Johnson: assets & liabilities 257Figure 127: Merck & Co., Inc.: revenues & profitability 260Figure 128: Merck & Co., Inc.: assets & liabilities 261Figure 129: Pfizer Inc.: revenues & profitability 264Figure 130: Pfizer Inc.: assets & liabilities 264Figure 131: United States pharmaceuticals market value forecast: $ million, 2010–15 265

To order this report:Pharmaceutical Industry: Pharmaceuticals - Global Group of Eight (G8) Industry Guide

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Wed, 23 May 2012 10:07:26 +0000

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

http://www.reportlinker.com/p0866960/Arthritis-Therapeutics-Market-to-2018---Novel-Oral-JAK-Inhibitors-and-Biologic-Disease-Modifying-Anti-Rheumatic-Drugs-DMARD-Will-Drive-Continued-Growth-Across-Key-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Summary

GBI Research's new report, "Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications", provides an expert insight into the global arthritis market and market forecast until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the top four arthritis therapeutic indications which are osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape of the top companies in the market and an analysis of the key trends in mergers and acquisitions, and licensing agreements involving arthritis therapies.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the global arthritis therapeutics market was estimated at $20.6 billion in 2010, during the forecast period the market grow at a Compound Annual Growth Rate (CAGR) of 7.2% between 2010 and 2018 to a $38 billion. The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010. The rheumatoid arthritis market was $14 billion in 2010. The market revenue is expected to increase to $26.9 billion by 2018 at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications. Top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

GBI Research analysis shows that the Research and Development (R&D) pipeline for the arthritis therapeutics market is strong. The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

Scope

- Data and analysis of the arthritis market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan. - Annualized market data for the osteoarthritis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis markets from 2004 to 2010, with forecasts to 2018.- Market Data on geographical landscape and therapeutic landscape including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Key drivers and restraints that have had a significant impact on the market - The competitive landscape of the arthritis market which includes companies such as Johnson & Johnson, Abbott, Amgen, Pfizer, Roche and Bristol-Myers Squibb.- Key M&A activities and licensing agreements that took place from 2005 to 2011 in the arthritis market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.- Device a more tailored country strategy by understanding the key drivers and barriers of the arthritis market.- Develop key strategic initiatives by understanding the key focus areas of the leading companies.- Accelerate and strengthen your market position by identifying the key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents1 Table of Contents 61.1 List of Tables 91.2 List of Figures 112 Arthritis Therapeutics Market to 2018 - Introduction 123 Arthritis Therapeutics Market to 2018 - Market Overview 143.1 Introduction 143.2 Revenue Forecasts for the Global Arthritis Therapeutics Market 153.2.1 Revenue 153.2.2 Annual Cost of Treatment 163.3 Treatment Usage Patterns 173.3.1 Diseased Population 183.3.2 Treatment Seeking Population 183.3.3 Diagnosis Population 183.3.4 Prescription Population 194 Arthritis Therapeutics Market to 2018 - Therapeutic Landscape 204.1 Osteoarthritis Therapeutics Market 204.1.1 Introduction 204.1.2 Epidemiology 214.1.3 Symptoms 214.1.4 Diagnosis 214.1.5 Diagnostic Imaging Techniques 224.1.6 Treatment 224.1.7 Revenue 254.1.8 Annual Cost of Treatment 264.1.9 Treatment Usage Patterns 274.1.10 Marketed Products 294.2 Drivers and Barriers for the Osteoarthritis Therapeutics Market 304.2.1 Drivers for the Osteoarthritis Therapeutics Market 304.2.2 Barriers for the Osteoarthritis Therapeutics Market 304.3 Opportunity and Unmet Need 314.4 Arthritis Therapeutics Market 324.4.1 Introduction 324.4.2 Epidemiology 334.4.3 Symptoms 334.4.4 Diagnosis 344.4.5 Diagnostic Techniques 344.4.6 Treatment 354.4.7 Non-Pharmacological Therapy 364.4.8 Surgical Treatment 364.4.9 Pharmacological Therapy 364.4.10 Revenue 374.4.11 Annual Cost of Treatment 384.4.12 Treatment Usage Patterns 394.4.13 Marketed products 414.5 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 424.5.1 Drivers for the Rheumatoid Arthritis Therapeutics Market 424.5.2 Barriers for the Rheumatoid Arthritis Therapeutics Market 424.6 Opportunity and Unmet Needs 434.7 Psoriatic Arthritis Therapeutics Market 434.7.1 Introduction 434.7.2 Epidemiology 444.7.3 Symptoms 444.7.4 Diagnosis 444.7.5 Diagnostic Techniques 444.7.6 Treatment 454.7.7 Non-Pharmacological Therapy 454.7.8 Pharmacological Therapy 454.7.9 Surgery 464.7.10 Revenue 464.7.11 Annual Cost of Treatment 474.7.12 Treatment Usage Patterns 484.7.13 Marketed Products 504.8 Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market 514.8.1 Drivers for the Psoriatic Arthritis Therapeutics Market 514.8.2 Barriers for the Psoriatic Arthritis Therapeutics Market 514.9 Opportunity and Unmet Needs 514.10 Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Market 524.10.1 Introduction 524.10.2 Epidemiology 524.10.3 Symptoms 534.10.4 Diagnosis 534.10.5 Treatment 544.10.6 Non-Pharmacological Therapy 544.10.7 Pharmacological Therapy 554.10.8 Surgery 564.10.9 Revenue 564.10.10 Annual Cost of Treatment 574.10.11 Treatment Usage Patterns 584.10.12 Marketed products 604.11 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market 604.11.1 Drivers for the Ankylosing Spondylitis Therapeutics Market 604.11.2 Barriers for the Ankylosing Spondylitis Therapeutics Market 604.12 Opportunity and Unmet Need 615 Arthritis Therapeutics Market to 2018 - Geographical Landscape 625.1 Revenue Analysis by Geography 625.2 The US 635.2.1 Revenue 635.2.2 Annual Cost of Treatment 655.2.3 Treatment Usage Patterns 665.3 Top Five European countries (UK, Germany, France, Italy and Spain) 685.3.1 Revenue 685.3.2 Annual Cost of Treatment 695.3.3 Treatment Usage Patterns 705.4 Japan 725.4.1 Revenue 725.4.2 Annual Cost of Treatment 735.4.3 Treatment Usage Patterns 746 Arthritis Therapeutics Market to 2018 - Product Pipeline Analysis 766.1 Introduction 786.1.1 Research and Development Pipeline – Osteoarthritis 786.2 Introduction 836.2.1 Research and Development Pipeline – Rheumatoid Arthritis 836.3 Introduction 956.3.1 Research and Development Pipeline – Psoriasis Arthritis 956.4 Introduction 966.4.1 Research and Development Pipeline – Ankylosing Spondylitis 966.5 Profiles of Promising Drugs in the Pipeline 986.5.1 Tofacitinib (CP-690550) 986.5.2 Ofatumumab 996.5.3 Secukinumab (AIN457) 996.5.4 Fostamatinib (R788) 1006.5.5 LY2127399 (Tabalumab) 1016.5.6 REGN88 (SAR153191) 1026.5.7 LT-NS001 1037 Arthritis Therapeutics Market to 2018 - Competitive Landscape 1047.1 Market Share Analysis 1047.1.1 Major Players 1047.2 Competitive Profile 1057.2.1 Roche 1057.2.2 Johnson & Johnson 1077.2.3 Pfizer 1087.2.4 Abbott Laboratories 1107.2.5 Bristol-Myers Squibb 1117.2.6 Amgen 1128 Arthritis Therapeutics Market to 2018 - Strategic Consolidations 1138.1 Mergers and Acquisitions 1138.1.1 Overview 1138.1.2 Major Merger and Acquisition Deals 1138.1.3 Possible Future Merger and Acquisition Deals 1198.2 Licensing Agreements 1208.2.1 Overview 1208.2.2 Major Licensing Deal 1208.3 Co-Development Agreements 1268.4 Deals by Geography 1328.5 Deals by Value 1339 Arthritis Therapeutics Market to 2018 - Appendix 1349.1 Market Definitions 1349.2 Abbreviations 1349.3 Sources 1359.4 Research Methodology 1369.4.1 Coverage 1369.4.2 Secondary Research 1369.4.3 Primary Research 1379.4.4 Forecasts 1379.4.5 Expert Panel Validation 1409.5 Contact Us 1409.6 Disclaimer 140

List of Tables

1.1 List of TablesTable 1: Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 15Table 2: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 16Table 3: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 16Table 4: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 17Table 5: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 17Table 6: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 18Table 7 : Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 25Table 8: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 26Table 9: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 26Table 10: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 26Table 11: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 27Table 12: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 28Table 13: Osteoarthritis Therapeutics Market, Marketed Products, 2010 29Table 14: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 37Table 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 37Table 16: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 38Table 17: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 38Table 18: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 39Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 40Table 20: Rheumatoid Arthritis Therapeutics-Marketed Products, 2010 41Table 21: Psoriatic Arthritis Therapeutics Market, Global, Revenue ($bn), 2004-2010 47Table 22: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018 47Table 23: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 47Table 24: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 48Table 25: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 49Table 26: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 49Table 27: Psoriatic Arthritis Therapeutics-Marketed Products, 2010 50Table 28: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2004-2010 56Table 29: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018 56Table 30: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 57Table 31: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 57Table 32: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2010 58Table 33: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018 59Table 34: Ankylosing Spondylitis Therapeutics-Marketed Products, 2010 60Table 35: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2010 63Table 36: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018 63Table 37: Arthritis Therapeutics Market, The US, Revenue ($bn), 2004-2010 64Table 38: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018 64Table 39: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2004-2010 65Table 40: Arthritis Therapeutics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82Table 60: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 82Table 61: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 84Table 62: Arthritis Therapeutics Market, Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 85Table 63: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 86Table 64: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 87Table 65: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 88Table 66: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 89Table 67: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 90Table 68: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 92Table 69: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 93Table 70: Arthritis Therapeutics Market-Rheumatoid Arthritis Pipeline, Development Stage Molecules, 2011 94Table 71: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 95Table 72: Arthritis Therapeutics Market-Psoriatic Arthritis Pipeline, Development Stage Molecules, 2011 96Table 73: Arthritis Therapeutics Market- Ankylosing Spondylitis Pipeline, Development Stage Molecules, 2011 97

List of Figures

1.2 List of FiguresFigure 1: Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 15Figure 2: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 16Figure 3: Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 17Figure 4: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 25Figure 5: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 26Figure 6: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 27Figure 7: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 37Figure 8: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 38Figure 9: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 39Figure 10: Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 46Figure 11: Psoriatic Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 47Figure 12: Psoriatic Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 48Figure 13: Ankylosing Spondylitis Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 56Figure 14: Ankylosing Spondylitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 57Figure 15: Ankylosing Spondylitis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2004-2018 58Figure 16: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2004-2018 62Figure 17: Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 64Figure 18: Arthritis Therapeutics Market, The US, Annual Cost of Treatment ($), 2004-2018 65Figure 19: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2018 66Figure 20: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2004-2018 68Figure 21: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2018 69Figure 22: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2018 70Figure 23: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2004-2018 72Figure 24: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2018 73Figure 25:Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2018 74Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133Figure 41: GBI Research Market Forecasting Model 139

Companies Mentioned

RocheJohnson & JohnsonPfizerAbbott LaboratoriesBristol-Myers SquibbAmgen

To order this report:Therapy Industry: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

Wed, 23 May 2012 09:38:13 +0000

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

PR Newswire

NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

http://www.reportlinker.com/p0866959/Antibacterials-Market-to-2017---Innovative-Anti-Infectives-that-Target-MDR-Gram-Negative-Pathogens-Offer-Significant-Revenue-Potential.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

Summary

GBI Research, the leading business intelligence provider, has released its latest report, "Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential", which provides key data, information and analysis for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections, atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europe and Japan).

This report offers a comprehensive insight into antibacterial market based on the seven indications covered. It provides a disease overview for each indication, market forecasting, drivers and barriers, key marketed products, pipeline information and deals information for each disease in the top seven markets, as well as profiles for the main companies operating in the market.

The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts to provide a comprehensive view of the antibacterials market.

The market is large and established, but still seeing good growth despite this due to the increasing problem of nosocomial infection and the increasing incidence of some bacterial diseases in the developed world. Despite several patent expiries, including of Levaquin, one of the highest selling antibacterials, growth will continue over the forecast period. Antibacterial stewardship programs for general practitioners and hospitals, aimed at countering the development of resistance in bacteria, will not significantly slow revenues in the forecast period. While the development of new antibacterials is not currently a hugely dynamic area, targeting multi-drug resistant TB and other indications will require innovative solutions in the future.

The antibacterials market is expected to reach $12.7 billion in 2017, growing from $11.3 billion in 2010 at a CAGR of 1.7%. The market is well served currently and patent expiries are slowing the overall growth. However, despite this saturation, hospital-acquired infections are providing an impetus to development.

Scope

- Overview of the global market for antibacterials.

- Breakdown of the market by region.

- Market analysis for each indication – including disease overviews, market forecasting, annual cost of therapy, treatment usage patterns, key marketed products and drivers and barriers.

- Comprehensive pipeline analysis by indications across all phases of development.

- Company profiles including SWOT analysis for major companies operating in the market.

- Key deals in the antibacterials space.

Reasons to buy

- Make more informed business decisions from the insightful and in-depth analysis of the antibacterials market.

- Identify the opportunities and challenges that exist within the antibacterials market.

- Build effective strategies to launch pipeline products.

- Identify the opportunities for collaboration with the participants in the antibacterials market.

Table of Contents

1 Table of Contents1 Table of Contents 51.1 List of Tables 101.2 List of Figures 122 Antibacterials - Introduction 143 Antibacterials - Overview 153.1 Bacterial Classification 153.1.1 Antimicrobial Spectrum 153.1.2 Bacterial Resistance 163.2 Antibacterial Classification 163.2.1 Cephalosporin Antibacterials 163.2.2 Penicillin Antibacterials 193.2.3 Quinolone Antibacterials 203.2.4 Macrolide Antibacterials 213.3 Global Revenues for Antibacterials 213.3.1 Global Revenue and Forecast 213.3.2 Revenue Share by Indication 233.4 The US 243.4.1 Total Revenues 243.5 Europe (The UK, France, Germany, Spain, Italy) 253.5.1 Total Revenues 253.6 Japan 273.6.1 Total Revenues 273.7 Drivers and Barriers for the Antibacterials Market 283.7.1 Drivers for the Antibacterials Market 283.7.2 Barriers for the Antibacterials Market 283.8 Opportunities 313.8.1 Alliances with Academic and Research Institutions are the Way Forward for Big Pharma 314 Tuberculosis 324.1 Overview 324.1.1 Microbiology 334.1.2 Diagnosis 334.1.3 Treatment 334.1.4 Prevention 344.2 Tuberculosis Therapeutics Market Size 354.2.1 Total Revenue 354.2.2 Average Annual Cost of Treatment (ACT) 384.2.3 Treatment Usage Patterns 394.3 Drivers and Barriers for the Tuberculosis Therapeutics Market 424.3.1 Drivers for the Tuberculosis Therapeutics Market 424.3.2 Barriers to the Tuberculosis Therapeutics Market 434.4 Product Profile of the Major Marketed Products in the Tuberculosis Market 434.4.1 Isoniazid (Isonicotinylhydrazine, INH) 434.4.2 Rifampin (RIF) 444.4.3 Pyrazinamide (PZA) 444.4.4 Ethambutol (EMB) 455 Pneumonia 465.1 Overview 465.1.1 Microbiology 465.1.2 Diagnosis 465.1.3 Treatment 475.1.4 Prevention 485.2 Pneumonia Therapeutics Market Size 495.2.1 Total Revenue 495.2.2 Annual Cost of Treatment (ACT) 525.2.3 Treatment Usage Patterns 535.3 Drivers and Barriers to the Pneumonia Therapeutics Market 555.3.1 Drivers for the Pneumonia Therapeutics Market 555.3.2 Barriers to the Pneumonia Antibacterials Market 555.4 Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market 575.4.1 Zyvox (linezolid) 575.4.2 Zosyn (piperacillin and tazobactum) 585.4.3 Levaquin (levofloxacin) 585.4.4 Avelox (moxifloxacin) 595.4.5 Omnicef (cefnidir) 595.4.6 Tygacil (tigecycline) 605.4.7 Doribax (doripenem) 616 Urinary Tract Infections 626.1 Overview 626.1.1 Cystitis 626.1.2 Urethritis 626.1.3 Pyelonephritis 626.1.4 Microbiology 626.1.5 Diagnosis 626.1.6 Urinalysis 626.1.7 Urine Culture 626.1.8 Treatment 636.1.9 Prevention 646.2 Urinary Tract Infection Therapeutics Market Size 646.2.1 Total Revenue 646.2.2 Annual Cost of Treatment (ACT) 676.2.3 Treatment Usage Patterns 686.3 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 706.3.1 Drivers for the UTI Therapeutics Market 706.3.2 Barriers for the UTI Therapeutics Market 706.4 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market 716.4.1 Doribax (doripenem) 716.4.2 Ciprofloxacin 726.4.3 Levaquin (levafloxacin) 736.4.4 Monurol (fosfomycin tromethamine) 746.4.5 Macrobid (nitrofurantoin) 747 Atypical Bronchitis 767.1 Overview 767.1.1 Microbiology 767.1.2 Diagnosis 767.1.3 Treatment 767.1.4 Prevention 767.2 Atypical Bronchitis Therapeutics Market Size 777.2.1 Total Revenue 777.2.2 Annual Cost of Treatment (ACT) 797.2.3 Treatment Usage Patterns 807.3 Drivers and Barriers for the Atypical Bronchitis Therapeutics Market 827.3.1 Drivers for the Atypical Bronchitis Therapeutics Market 827.3.2 Barriers for the Atypical Bronchitis Therapeutics Market 827.4 Marketed Products 838 Tonsillitis 848.1 Overview 848.1.1 Microbiology 848.1.2 Diagnosis 848.1.3 Treatment 848.1.4 Prevention 858.2 Tonsillitis Therapeutics Market Size 858.2.1 Total Revenue 858.2.2 Annual Cost of Treatment (ACT) 878.2.3 Treatment Usage Patterns 888.3 Drivers and Barriers for the Tonsillitis Therapeutics Market 908.3.1 Drivers for the Tonsillitis Therapeutics Market 908.3.2 Barriers for the Tonsillitis Therapeutics Market 908.4 Marketed Products 918.4.1 Spectracef 919 Sinusitis 929.1 Overview 929.1.1 Frontal Sinusitis (located behind the forehead) 929.1.2 Ethmoid Sinusitis (behind the bridge of the nose) 929.1.3 Sphenoid Sinusitis (behind the eyes) 929.1.4 Maxillary Sinusitis (behind the cheeks) 929.1.5 Acute Sinusitis 929.1.6 Chronic Sinusitis 929.1.7 Microbiology 939.1.8 Diagnosis 939.1.9 Treatment 939.1.10 Prevention 939.2 Sinusitis Therapeutics Market Size 949.2.1 Total Revenue 949.2.2 Annual Cost of Therapy 969.2.3 Therapeutic Patterns 979.3 Drivers and Barriers for the Sinusitis Therapeutics Market 989.3.1 Drivers for the Sinusitis Therapeutics Market 989.3.2 Barriers for the Sinusitis Therapeutics Market 999.4 Marketed Products 999.4.1 Augmentin 999.4.2 Levaquin 1009.4.3 Doryx 10110 Otitis Media 10210.1 Overview 10210.1.1 Acute 10210.1.2 Serous 10210.1.3 Chronic Suppurative 10210.2 Otitis Media Therapeutics Market Size 10310.2.1 Total Revenue 10310.2.2 Annual Cost of Therapy 10510.2.3 Therapeutic Patterns 10610.3 Drivers and Barriers for the Otitis Media Therapeutics Market 10710.3.1 Drivers for the Otitis Media Therapeutics Market 10710.3.2 Barriers for the Otitis Media Therapeutics Market 10710.4 Marketed Products 10810.4.1 Amoxicillin 10811 Antibacterials - Pipeline Analysis 10911.1 Introduction 10911.2 Global Tuberculosis Market: Pipeline Analysis 11011.2.1 Overview 11011.2.2 Research and Development Pipeline - Phase III 11011.2.3 Research and Development Pipeline - Phase II 11111.2.4 Research and Development Pipeline - Phase I 11211.2.5 Research and Development Pipeline - Preclinical 11211.3 Global Pneumonia Therapeutics Market: Pipeline Assessment 11311.3.1 Overview 11311.3.2 NDA Filed 11311.3.3 Phase III 11311.3.4 Phase II 11411.3.5 Phase I 11511.3.6 Preclinical 11511.4 Global Urinary Tract Infection Therapeutics Market: Pipeline Assessment 11611.4.1 Overview 11611.4.2 Phase III 11611.4.3 Phase II 11711.4.4 Phase I 11711.4.5 Discovery 11711.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment 11811.5.1 Phase I 11811.6 Global Tonsillitis Therapeutics Market: Pipeline Assessment 11811.6.1 Overview 11811.7 Global Sinusitis Therapeutics Market: Pipeline Assessment 11811.7.1 Phase I 11811.8 Global Otitis Media Therapeutics Market: Pipeline Assessment 11911.8.1 Overview 11911.8.2 Phase II 11911.8.3 Preclinical 11912 Antibacterials: Competitive Landscape 12012.1 Major Players 12012.2 Major Company Profiles 12012.2.1 Pfizer 12012.2.2 Sanofi 12112.2.3 Bayer 12212.2.4 GlaxoSmithKline 12312.2.5 AstraZeneca 12412.2.6 Cubist 12512.2.7 Daiichi Sankyo 12612.2.8 Tetraphase 12712.2.9 Johnson and Johnson 12813 Antibacterials - Strategic Consolidations 12913.1 Overview - Antibacterials Market 12913.1.1 Deals by Indication 12913.1.2 Deals by Year 13013.2 Tuberculosis 13013.2.1 Mergers and Acquisitions 13013.2.2 Licensing and Co-Developments 13013.3 Pneumonia 13313.3.1 Furiex Pharmaceuticals Enters into Licensing Agreement with Janssen Pharmaceutica for JNJ-Q2 (April 19, 2011) 13313.3.2 TaiGen Biotechnology Amends its Licensing Agreement with Warner Chilcott for Nemonoxacin (October 14, 2010) 13313.3.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29, 2010) 13413.3.4 Paratek Pharmaceuticals Enters into Licensing Agreement with Novartis (October 8, 2009) 13413.3.5 AstraZeneca Enters into Co-Development Agreement with Forest Laboratories (August 12, 2009) 13413.3.6 Protea Vaccine Enters into Co-Development Agreement with GlaxoSmithKline Biologicals (June 16, 2009) 13413.3.7 Sanofi-aventis Enters into Licensing and Collaboration Agreement with Novozymes (December 22, 2008) 13513.3.8 Laboratorios Farmaceuticos ROVI Enters into Co-Development Agreement with Sanofi Pasteur (May 5, 2008) 13513.3.9 Aridis Pharmaceuticals Enters into Licensing Agreement with University of Iowa Research (February 19, 2008) 13513.3.10 Nektar Therapeutics Enters into Co-Development Agreement with Bayer HealthCare (August 6, 2007) 13513.3.11 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE (January 4, 2007) 13613.4 UTI 13613.4.1 Teva Pharmaceutical Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey (February 21, 2008) 13613.4.2 NanoBio Enters into Licensing Agreement with University of Michigan (April 20, 2011) 13613.4.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29, 2010) 13613.4.4 Depomed Amends Licensing Agreement with Madaus (April 30, 2009) 13713.5 Atypical Bronchitis 13713.5.1 Teva Pharmaceutical Industries Completes Acquisition of Ratiopharm (August 10, 2010) 13713.6 Tonsillitis 13713.6.1 Meiji Seika Enters into Licensing Agreement with Cornerstone Biopharma (November 9, 2006) 13713.7 Sinusitis 13813.7.1 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE (January 4, 2007) 13813.8 Otitis Media 13813.8.1 MerLion Pharmaceuticals Enters into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin (January 11, 2011) 13813.8.2 OctoPlus Enters into Licensing Agreement with Green Cross (November 22, 2006) 13814 Antibacterials - Appendix 13914.1 Market Definition 13914.2 Abbreviations 13914.3 Sources 14114.4 Research Methodology 14114.4.1 Coverage 14214.4.2 Secondary Research 14214.4.3 Primary Research 14214.5 Forecasting 14314.5.1 Epidemiology-based Forecasting 14314.5.2 Expert Panels Validation 14414.6 Geographical Landscape 14414.7 Pipeline Analysis 14414.8 Competitive Landscape 14414.9 Contact Us 14414.10 Disclaimer 145

List of Tables

1.1 List of TablesTable 1: Antibacterials Market, Classification, Cephalosporin Antibacterials by Generations 18Table 2: Antibacterials, Classification, Penicillin Antibacterials 20Table 3: Antibacterials Market, Global, Revenue, $bn, 2002-2010 21Table 4: Antibacterials Market, Global, Revenue Forecasts, $bn, 2010-2017 22Table 5: Antibacterials Market, The US, Revenue, $bn, 2002-2010 24Table 6: Antibacterials Market, The US, Revenue Forecasts, $bn, 2010-2017 24Table 7: Antibacterials Market, EU-5, Revenue, $bn, 2002-2010 25Table 8: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2010-2017 25Table 9: Antibacterials Market, Japan, Revenue, $m, 2002-2010 27Table 10: Antibacterials Market, Japan, Revenue Forecasts, $m, 2010–2017 27Table 11: Tuberculosis Therapeutics Market, Global, Revenue, $m, 2002-2010 35Table 12: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 35Table 13: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2010 36Table 14: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 36Table 15: Tuberculosis Antibacterials Market, Global, ACT, $, 2002-2010 38Table 16: Tuberculosis Antibacterials Market, Global, ACT, $, 2010-2017 38Table 17: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2002-2010 39Table 18: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2010-2017 39Table 19: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2010 40Table 20: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2010-2017 40Table 21: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2002-2010 41Table 22: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2010-2017 41Table 23: Pneumonia Therapeutics Market, Global, Revenue, $m, 2002-2010 49Table 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 49Table 25: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 50Table 26: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 51Table 27: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 52Table 28: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 52Table 29: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010 53Table 30: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017 53Table 31: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 64Table 32: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 64Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 65Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 66Table 35: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 67Table 36: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 67Table 37: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 68Table 38: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 68Table 39: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 77Table 40: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 77Table 41: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 78Table 42: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 78Table 43: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 79Table 44: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 79Table 45: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010 80Table 46: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017 80Table 47: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 85Table 48: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 85Table 49: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 86Table 50: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 86Table 51: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 87Table 52: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 87Table 53: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 88Table 54: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 88Table 55: Sinusitis Therapeutics Market, Global, Revenue, $bn, 2002-2010 94Table 56: Sinusitis Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017 94Table 57: Sinusitis Therapeutics Market, Global, Revenue by Country, $bn 2002-2010 95Table 58: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-2017 95Table 59: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 96Table 60: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 96Table 61: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 97Table 62: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 97Table 63: Otitis Media Therapeutics Market, Global, Revenue, $m, 2002-2010 103Table 64: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 103Table 65: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 104Table 66: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 104Table 67: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 105Table 68: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 105Table 69: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 106Table 70: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 106Table 71: Tuberculosis Therapeutics Market, Pipeline, Phase III Molecules, 2010 110Table 72: Tuberculosis Therapeutics Market, Pipeline, Phase II Molecules, 2010 111Table 73: Tuberculosis Therapeutics Market, Pipeline, Phase I Molecules, 2010 112Table 74: Tuberculosis Therapeutics Market, Pipeline, Preclinical Molecules, 2010 112Table 75: Pneumonia Therapeutics Market, Pipeline, NDA Filed Molecules, 2010 113Table 76: Pneumonia Therapeutics Market, Pipeline, Phase III Molecules, 2010 113Table 77: Pneumonia Therapeutics Market, Pipeline, Phase II Molecules, 2010 114Table 78: Pneumonia Therapeutics Market, Pipeline, Phase I Molecules, 2010 115Table 79: Pneumonia Therapeutics Market, Pipeline, Preclinical Molecules, 2010 115Table 80: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010 116Table 81: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010 117Table 82: Urinary Tract Infection Therapeutics Market, Pipeline, Phase I Molecules, 2010 117Table 83: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Molecules, 2010 117Table 84: Atypical Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118Table 85: Sinusitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118Table 86: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010 119Table 87: Otitis Media Therapeutics Market, Pipeline, Preclinical Molecules, 2010 119

List of Figures

1.2 List of FiguresFigure 1: Antibacterials Market, Global, Revenue Forecasts, $bn, 2002-2017 21Figure 2: Antibacterials Market, Global, Revenue Share by Indication, %, 2010 23Figure 3: Antibacterials Market, The US, Revenue Forecasts, $bn, 2002-2017 24Figure 4: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2002-2017 25Figure 5: Antibacterials Market, Japan, Revenue Forecasts, $m, 2002-2017 27Figure 6: Tuberculosis, Recommended Initial Therapy, 2011 33Figure 7: Tuberculosis, Treatment Flow Pattern, 2011 34Figure 8: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 35Figure 9: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 36Figure 10: Tuberculosis Therapeutics Market, Global, ACT, $, 2002-2017 38Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2002-2017 39Figure 12: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2017 40Figure 13: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2002-2017 41Figure 14: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2011 48Figure 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 49Figure 16: Pneumonia Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 50Figure 17: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 52Figure 18: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 53Figure 19: Urinary Tract Infection Therapeutics Market, Treatment of Uncomplicated UTI, 2011 63Figure 20: Urinary Tract Infection Therapeutics Market, Treatment of Complicated UTI, 2011 63Figure 21: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 64Figure 22: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 65Figure 23: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 67Figure 24: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 68Figure 25: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 77Figure 26: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 78Figure 27: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 79Figure 28: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 80Figure 29: Tonsillitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 85Figure 30: Tonsillitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 86Figure 31: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 87Figure 32: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 88Figure 33: Sinusitis Therapeutics Market, Global, Revenue Forecast, $bn, 2002-2017 94Figure 34: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-2017 95Figure 35: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 96Figure 36: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 97Figure 37: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 103Figure 38: Otitis Media Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 104Figure 39: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 105Figure 40: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 106Figure 41: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 110Figure 42: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 113Figure 43: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 116Figure 44: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 119Figure 45: Antibacterial Therapeutics Market, SWOT Analysis of Pfizer, 2010 120Figure 46: Antibacterial Therapeutics Market, Sanofi SWOT Profile, 2010 121Figure 47: Antibacterials Market, Bayer SWOT Profile, 2010 122Figure 48: Antibacterials Market, GSK SWOT Profile, 2010 123Figure 49: Antibacterials Market, AstraZeneca SWOT Profile, 2010 124Figure 50: Antibacterial, Cubist SWOT Profile, 2010 125Figure 51: Antibacterial, Daiichi-Sankyo SWOT Profile, 2010 126Figure 52: Antibacterial, Tetraphase SWOT Profile, 2010 127Figure 53: Antibacterial, Johnson & Johnson SWOT Profile, 2010 128Figure 54: Antibacterials Market, Global, Deals by Indication (%), 2011 129Figure 55: Antibacterials Market, Global, Deals by Year (%), 2004-2011 130

Companies Mentioned

PfizerSanofiBayerGlaxoSmithKlineAstraZenecaCubistDaiichi SankyoTetraphaseJohnson and Johnson

To order this report:Therapy Industry: Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

Wed, 23 May 2012 07:00:00 +0000

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

PR Newswire

LONDON, May 23, 2012 /PRNewswire/ --

According to Cold Chain IQ findings, nearly 30% of individuals surveyed reported temperature excursions in 6% or more of their temperature sensitive pharmaceutical product. Temperature excursions of pharmaceutical products can not only result in product losses, but also endanger patient lives.

Cold Chain IQ presents a new report examining temperature excursions in the distribution chain for clinical and commercial products and leading strategies that the pharmaceutical industry is employing to improve the storage and handling of temperature sensitive products.

Cold Chain IQ, the online resource for the temperature controlled supply industry has published the state of the industry report "Operating a Global Temperature Controlled Supply Chain."

This definitive research report looks at technologies and strategies the industry is employing to leverage partnerships and streamline processes in supply chains of temperature sensitive products.

Over the past year Cold Chain IQ conducted interviews with over 100 experts from all stages of the pharmaceutical and medical distribution chain from logistics to quality assurance, regulators to manufacturers. In this report we share their key challenges and strategies to overcome these.

Contributors include global heads of cold chain and experts from Latin America IMF, Pfizer, Word Courier Group, Roche, Eli Lilly, Modality Solutions, AMAG, Merck, Exelsius Cold Chain, Novo Nordisk, DHL, MacroGenics, Laminar Medica, Logistics Institute of Asia Pacific and South African Refrigerated Distribution Association as well as unique perspective from 300+ global attendees from the 11th Annual Cool Chain Logistics Europe industry forum.

The 28 page report features in-depth insight on the rise of emerging markets, reverse logistics, the increased push towards eco initiatives, CRT and quality management systems as well as a detailed overview of the industry.

"We predict 8 of the top 10 best-selling global drug products will require cold chain storage and handling by 2016 - this report is essential for anyone competing in the BioPharma industry," said Courtney Becker-James, Director, Cold Chain IQ.

Key Findings:

96% consider cold chain or temp control a core competency of their logistics provider
BRIC in 5 years: China will present the greatest opportunity
63% said finding cost-effective solutions / products is their key challenge in the storage and distribution of CRT and ambient products
71% of pharmaceutical distribution professionals plan to increase investment over the next 10 years

To learn the rest of the results and conclusions, read the full report here:

http://www.coldchainiq.com/supply-chain-security/white-papers/research-report-operating-a-global-temperature-con/

ColdChainIQ.com is designed for the life science logistics and quality community to share ideas, expertise and solutions, and provides members with cutting edge information and expertise as well as the opportunity to network with both their peers and key industry authorities.

For more information contact Cold Chain IQ on info@coldchainiq.com

Andrea Charles
Editor
Andrea.charles@iqpc.co.uk

Sumit Dutta
Marketing Manager
Sumit.dutta@iqpc.co.uk

IQPC
129 Wilton Road, Victoria, London SW1V 1JZ
+44(0)207-368-9300

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

Wed, 23 May 2012 07:00:00 +0000

New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments

PR Newswire

LONDON, May 23, 2012 /PRNewswire/ --

Cold Chain IQ, the online resource for the temperature controlled supply industry has published the state of the industry report "Operating a Global Temperature Controlled Supply Chain."

This definitive research report looks at technologies and strategies the industry is employing to leverage partnerships and streamline processes in supply chains of temperature sensitive products.

Key Findings:

96% consider cold chain or temp control a core competency of their logistics provider
BRIC in 5 years: China will present the greatest opportunity
63% said finding cost-effective solutions / products is their key challenge in the storage and distribution of CRT and ambient products
71% of pharmaceutical distribution professionals plan to increase investment over the next 10 years

To learn the rest of the results and conclusions, read the full report here:

http://www.coldchainiq.com/supply-chain-security/white-papers/research-report-operating-a-global-temperature-con/

SOURCE ColdChainIQ.com

New Zoning to Highlight High-Growth Sectors at China Pharma Events

Wed, 23 May 2012 02:00:00 +0000

New Zoning to Highlight High-Growth Sectors at China Pharma Events

PR Newswire

AMSTERDAM, May 23, 2012 /PRNewswire-Asia/ -- Leading events organiser UBM Live( http://www.ubmlive.com ) today announced details of its annual schedule of China events for the global pharmaceutical market. Set to be hosted from 26th to 28th June at the SNIEC in Shanghai, CPhI China for pharmaceutical ingredients, and ICSE China for contract and outsourced services, will be co-located with BioPh China for the biopharmaceutical sector, InnoPack China for innovative packaging services and solutions, and LABWorld China for laboratory and analytical equipment needs. The combined events are expected to host more than 27,000 attendees and 1,700 diverse exhibitors. Attendees of the 2012 China Pharma Portfolio of events will also be able to take advantage of the introduction of zoning, designed to highlight high-growth sectors within the Chinese market and facilitate easier navigation of the events for maximised visitor ROI.

(Logo: http://www.prnasia.com/sa/2010/04/19/20100419602891.jpg )

(Logo: http://www.prnasia.com/sa/2012/02/22/20120222113118191988-l.jpg )

"The size and synergies of CPhI China, ICSE China and the co-located events create a dedicated marketplace for companies to find products and services, including standard and custom APIs. In the Asian pharma market, an increased emphasis has been placed on producing high quality drugs faster as many blockbuster drug patents expire. There is a large interest in generics and biosimilars, as the market demands better versions of drugs at a cheaper price. Statistics have shown that the Chinese market could double as the country improves its health care systems and regulations and IMS Health projected that drug revenue in China would grow by $40 billion through 2013(Source 1)," UBM Brand Director, Haf Cennydd noted. "Active Pharmaceutical Ingredients (APIs) make up more than 50% of the export value of China's pharmaceutical trade and is it estimated that the Chinese market for APIs will witness a compound growth rate of 18% from 2010 to 2017(Source 2). In this flourishing environment CPhI China, ICSE China and co-located events are the only events of their kind that can offer direct access to so many sectors of the Chinese pharmaceutical industry."

The UBM Live annual schedule of Pharmaceutical events also includes CPhI South East Asia (10-12 May, 2012 at the Jakarta International Expo in Indonesia), ICSE USA (22-23 May, 2012 at the Pennsylvania Convention Centre in Philadelphia, PA), CPhI, ICSE and BioPh South America (21-23 August, 2012 at the Transamerica Expo Center in Sao Paulo, Brazil), CPhI Worldwide, ICSE, P-MEC and InnoPack (9-11 October, 2012 at the Feria de Madrid, Spain), CPhI and P-MEC India (21-23 November, 2012 at the Bombay Exhibition Centre in Mumbai) and CPhI, ICSE, P-MEC and Pharmatec Japan (24-26 April, 2013 at the Tokyo Big Sight Exhibition Centre in Japan).

Sources:

(1) Manufacturing.net: "China could be 3rd largest pharma market by 2011"

(2) CHEManager Europe: "APIs in China: Pharma Industry Booming in Asia"

Notes for Editors:

Media Enquiries: Company Enquiries:

Impress Labs UBM Live

Global (excl. North America): Richard Kerns Haohao Chen

richard@impresslabs.com Tel: + 31-(0)-20-40-99-593

Tel: + 44-161-728-5880

North America: Beth Willers

beth@impresslabs.com

Tel: +1-503-928-7828

SOURCE　UBM Live

Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

Tue, 22 May 2012 19:41:57 +0000

Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.

PR Newswire

AUSTIN, Texas, May 22, 2012 /PRNewswire/ -- Prodigy Generics, a division of Prodigy Health Supplier Corporation (PHS), has launched injectable irinotecan. Irinotecan is the generic equivalent of the branded drug Camptosar by Pfizer.

Prodigy partnered with eVenus Pharmaceutical Laboratories to develop a portfolio of oncology products. Irinotecan is the first of several ANDAs being developed through the partnership that will add consistent supply and exceptional value to the U.S. injectable market, which has experienced record levels of shortages in the last year.

Irinotecan is indicated for use in the treatment of cancer, primarily colon cancer. It's used in the FOLFIRI chemotherapy regimen consisting of infusional 5-fluorouracil, leucovorin, and irinotecan. Irinotecan is available in 2ML (20 MG per ML) and 5ML (20 MG per ML).

"This launch represents an important milestone for Prodigy. Irinotecan is a drug that was on the FDA drug shortage list in the last year and is a great addition to our expanding generic drug pipeline. We could not be more excited about our partnership with eVenus to add consistent supply to the market," states Jon Houssian, President of Prodigy Generics.

Prodigy Health Supplier Corporation (PHS) was established in 2001 and is based in Austin, Texas. Since inception PHS has been a consistent and dependable supplier in the bio-pharmaceutical industry and has grown into one of the leading suppliers of plasma derivatives and injectables in the United States.

eVenus Pharmaceutical Laboratories Inc., a wholly owned subsidiary of Jiangsu Hengrui Medicine Co, Ltd., was established in the United States in 2009. The company, located in Cranbury, New Jersey, is based on a development and manufacturing history that spans over 40 years.

SOURCE Prodigy Health Supplier Corporation

Pfizer Teams With EatingWell To Launch Free Mobile App

Tue, 22 May 2012 14:24:25 +0000

Pfizer Teams With EatingWell To Launch Free Mobile App

Lipitor For You "Recipes 2 Go" App Helps Consumers Manage Heart Health on the Go

PR Newswire

NEW YORK, May 22, 2012 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and EatingWell Media Group, publisher of EatingWell Magazine and part of Meredith Corporation (NYSE: MDP), today announced the launch of Pfizer's Lipitor For You "Recipes 2 Go" mobile application ("app"), marking the first time Pfizer has released a consumer mobile app for a prescription product in the U.S.

(Logo: http://photos.prnewswire.com/prnh/20090810/CG58830LOGO)

The Lipitor For You "Recipes 2 Go" app is available for free from the App Store on iPhone, iPod touch and iPad, at www.itunes.com/appstore, and for Android phones and tablets from Google Play (www.play.google.com).

The "Recipes 2 Go" app offers consumers a variety of resources that can help to manage heart health anytime, anywhere. The app includes access to healthy recipes for appetizers, entrees, side dishes, snacks and desserts; a shopping list feature; and tips on portion sizes and exercise.

The Lipitor For You "Recipes 2 Go" app includes:

200 healthy recipes from EatingWell with easy-to-follow instructions and beautiful full-color photos
Intuitive categories and practical search feature to help find specific recipes
An easy-to-use shopping list that makes planning healthy meals simple
A "Favorites" functionality that allows users to keep their favorite recipes at their fingertips
A built-in timer
A copy of the LIPITOR $4 Co-Pay Card where Pfizer Lipitor for You participants can save their unique ID number to always have their card on hand when refilling their LIPITOR® (atorvastatin calcium) tablets prescription

Pfizer began working with EatingWell in 2009, licensing the brand's healthy recipes for the LIPITOR My Heart Wise website.

"The launch of a mobile app solution in conjunction with Pfizer is an important step toward helping to make heart-healthy living more convenient for today's on-the-go consumers," said Larry Sommers, General Manager, Digital Media and Business Development, EatingWell. "Our team of registered dietitians, nutrition and Test Kitchen experts has created custom healthy-eating solutions to inspire consumers to make healthy eating a way of life."

"Taking a cholesterol-lowering medication like LIPITOR is just part of the equation for maintaining a healthy lifestyle," said Greg Reeder, Senior Director, Team Leader, US Brands, Established Products Business Unit, Pfizer Inc. "The healthy recipes from our partnership with EatingWell gives Pfizer another innovative way to educate patients on the importance of managing cholesterol."

The Lipitor For You "Recipes 2 Go" app extends the newly launched Lipitor For You and Smart Living website (www.lipitorsmartliving.com), which features over 500 additional healthy recipes from EatingWell, helping to inspire patients to cook delicious meals that are compatible with their treatment goals. Statistics show that one in five adults over the age of 20 in the U.S. has high cholesterol, which is a major risk factor for cardiovascular disease, including heart attack and stroke.

ABOUT EATINGWELL
EatingWell is a fast-growing media brand that focuses exclusively on the expanding healthy-eating sector. EatingWell is positioned to be the leading source of science-based nutrition advice; delicious, easy and healthy recipes and useful shopping information. The brand has rapidly diversified from producing its flagship bimonthly EatingWell Magazine (which now reaches more than 3 million readers) to multiple formats, including a content-rich website (www.eatingwell.com) that reaches more than 4 million unique visitors a month, content and brand licensing, custom publishing and consumer cookbooks and health books. EatingWell Media Group was acquired by Meredith Corporation, the nation's leading media and marketing company serving women, in June 2011.

ABOUT Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

ABOUT LIPITOR:
LIPITOR (atorvastatin calcium) tablets are a prescription medicine that is used along with a low-fat diet. It lowers the LDL ("bad") cholesterol and triglycerides in your blood. It can raise your HDL ("good") cholesterol as well. LIPITOR can lower the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as age, smoking, high blood pressure, low HDL, or family history of early heart disease.

LIPITOR can lower the risk for heart attack or stroke in patients with diabetes and risk factors such as diabetic eye or kidney problems, smoking, or high blood pressure.

IMPORTANT SAFETY INFORMATION
LIPITOR (atorvastatin calcium) tablets are not for everyone, including anyone who has previously had an allergic reaction to LIPITOR (atorvastatin calcium) tablets. It is not for those with liver problems. And it is not for women who are nursing, pregnant or may become pregnant.

If you take LIPITOR (atorvastatin calcium) tablets, tell your doctor if you feel any new muscle pain or weakness. This could be a sign of rare but serious muscle side effects. Tell your doctor about all your medical conditions and all medications you take. This may help avoid serious drug interactions. Your doctor should do blood tests to check your liver function before starting LIPITOR (atorvastatin calcium) tablets and during your treatment if you have symptoms of liver problems. Tell your doctor if you have diabetes. Elevated blood sugar levels have been reported with statins, including LIPITOR (atorvastatin calcium) tablets.

Common side effects are diarrhea, upset stomach, muscle and joint pain, and changes in some blood tests.

LIPITOR $4 Co-Pay Card Terms and Conditions
By using the LIPITOR $4 Co-Pay Card (the "Card"), you acknowledge that you currently meet the eligibility criteria and will comply with the terms & conditions described below:

This Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as "La Reforma de Salud"]).

The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs which reimburse you for the entire cost of your prescription drugs.

To qualify for this offer, your out-of-pocket expense must be greater than $4 per prescription. If your out-of-pocket expenses for a 1-month supply (30 tablets) are $79 or less, you will pay $4 for a 1-month supply. If your out-of-pocket expenses for a 1-month supply (30 tablets) exceed $79, you qualify for up to $75 in savings for a 1-month supply. In either case, you can only qualify for up to $1,000 of savings per calendar year. After maximum of $1,000, you will pay usual monthly out-of-pocket costs.

You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf.

The Card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law.

This Card cannot be combined with any other rebate/coupon, free trial or similar offer for the specified prescription.

The Card will be accepted only at participating pharmacies.

This Card is not health insurance.

Offer good only in the U.S. and Puerto Rico.

The Card is limited to 1 per person during this offering period and is not transferable. Offer limited to 1 use per month.

Pfizer reserves the right to rescind, revoke or amend the program without notice at any time.

Card and Program expires 12/31/2014.

No membership fees.

For reimbursement when using a non-participating pharmacy/mail order: Pay for LIPITOR prescription and mail copy of original pharmacy receipt (cash register receipt NOT valid) with product name, date and amount circled to:
LIPITOR Co-Pay Card
6501 Weston Parkway, Suite 370
Cary, NC 27513

Be sure to include a copy of the front of your Co-Pay Card, your name and mailing address.

SOURCE Meredith Corporation

Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Tue, 22 May 2012 14:21:13 +0000

Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

PR Newswire

NEW YORK, May 22, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0794929/Commercializing-Pancreatic-Cancer-Drugs-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This report will excel your competitive awareness and decrease your decision making time in managing pancreatic cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer. BioSeeker has applied its unique drug assessment methodology to stratify the pancreatic cancer drug pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of pancreatic cancer drugs is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 37 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the pancreatic cancer drugs in general.

* Nine out of every ten drug target strategies in Phase III and Phase II development are new to pancreatic cancer drugs.

* The greatest number of new target strategies are found in Phase II (37%) and Phase I (18%) development.

* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of pancreatic cancer drugs, which represent almost 80% of the entire pipeline.

* Besides Reformulated drugs, it is Protein and Peptide based pancreatic cancer drugs that have the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies.

* The highest number of described drug target strategies of pancreatic cancer drugs belongs to Pfizer, Hoffmann-La Roche, Novartis and AstraZeneca.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any pancreatic cancer drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights™ 5

2.1 Cancer Focus Areas 5

2.2 Subscribe Today and Start Saving 6

2.2.1 Type of License 6

2.3 Additional Information 6

2.4 BioSeeker Group's Oncology Team 6

3 Methodology 7

3.1 Cancer Highlights'™ Five Pillar Drug Assessment 7

4 Table of Contents 9

4.1 List of Figures 19

4.2 List of Tables19

5 Introduction 27

5.1 The Scope of this Report 27

5.2 Definitions 30

5.3 Abbreviations 30

6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 31

6.1 Drug Repositioning in Oncology 31

6.2 Introduction to Targets of Pancreatic Cancer Drugs 32

6.2.1 Carboxy-lyase Activity Targets 39

6.2.2 Catalytic Activity Targets 40

6.2.3 Cell Adhesion Molecule Activity Targets 51

6.2.4 Chaperone Activity Targets 59

6.2.5 Cofactor Binding Targets 60

6.2.6 Cysteine-type Peptidase Activity Targets 62

6.2.7 Cytokine Activity Targets 69

6.2.8 DNA Binding Targets 75

6.2.9 DNA Repair Protein Targets 77

6.2.10 DNA Topoisomerase Activity Targets 80

6.2.11 DNA-directed DNA Polymerase Activity Targets 85

6.2.12 Extracellular Ligand-gated Ion Channel Activity Targets 92

6.2.13 Extracellular Matrix Structural Constituent Targets 94

6.2.14 G-protein Coupled Receptor Activity Targets 98

6.2.15 Growth Factor Activity Targets 108

6.2.16 GTPase Activity Targets 114

6.2.17 Hormone Activity Targets 123

6.2.18 Hydrolase Activity Targets 124

6.2.19 Ion Channel Activity Targets 125

6.2.20 Kinase Activity Targets 126

6.2.21 Kinase Binding Targets 138

6.2.22 Kinase Regulator Activity Targets 139

6.2.23 Ligand-dependent Nuclear Receptor Activity Targets 143

6.2.24 Ligase Activity Targets 144

6.2.25 Lipase activity 150

6.2.26 Lipid kinase activity 151

6.2.27 Lipid Phosphatase Activity Targets 154

6.2.28 Molecular Function Unknown Targets 155

6.2.29 Motor Activity Targets 165

6.2.30 Oxidoreductase Activity Targets 167

6.2.31 Peptidase Activity Targets 173

6.2.32 Peptide Hormone Targets 183

6.2.33 Peroxidase Activity Targets 185

6.2.34 Protein Binding Targets 186

6.2.35 Protein Serine/Threonine Kinase Activity Targets 188

6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 213

6.2.37 Protein Tyrosine Phosphatase Activity Targets 218

6.2.38 Protein-tyrosine Kinase Activity Targets 226

6.2.39 Receptor Activity Targets 237

6.2.40 Receptor Binding Targets 255

6.2.41 Receptor Signaling Complex Scaffold Activity Targets 260

6.2.42 RNA Binding Targets 264

6.2.43 RNA-directed DNA Polymerase Activity Targets 265

6.2.44 Serine-type Peptidase Activity Targets 266

6.2.45 Structural Constituent of Cytoskeleton Targets 271

6.2.46 Structural Molecule Activity Targets 273

6.2.47 Transcription Factor Activity Targets 274

6.2.48 Transcription Regulator Activity Targets 292

6.2.49 Transferase Activity Targets 298

6.2.50 Translation Regulator Activity Targets 299

6.2.51 Transmembrane Receptor Activity Targets 301

6.2.52 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 304

6.2.53 Transporter Activity Targets 340

6.2.54 Unclassified Targets 345

6.2.55 Voltage-gated Ion Channel Activity Targets 346

6.2.56 Other Targets 347

6.3 The Cancer Genome Project and Targets of Pancreatic Cancer Drugs 348

6.3.1 Targets of Pancreatic Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 348

6.4 Pancreatic Cancer Therapeutics is Stimulated by Available Structure Data on Targets 354

6.5 Target-Target Interactions among Identified Targets of Pancreatic Cancer Drugs 358

6.6 The Drug-Target Competitive Landscape 362

6.7 Protein Expression Levels of Identified Targets of Pancreatic Cancer Drugs 366

6.8 Pathway Assessment of Pancreatic Cancer Drugs 369

6.8.1 Tools for Analysis of Cancer Pathways 370

6.8.2 Pathway Assessment 371

7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development 423

7.1 Registered to Marketed: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 425

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 426

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 428

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 433

7.5 Preclinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 436

7.6 Drug Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 438

7.7 Target Strategy Development Profiles of Pancreatic Cancer Drugs 440

7.7.1 Marketed 444

7.7.2 Phase III 447

7.7.3 Phase II 462

7.7.4 Phase I 522

7.7.5 Preclinical 552

7.7.6 Suspended 575

7.7.7 Ceased 577

7.8 The Competition Through Close Mechanistic Approximation of Pancreatic Cancer Drugs 609

8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy 613

8.1 Small Molecules 615

8.1.1 Background 615

8.1.2 Target Strategies of Small Molecule Drugs 616

8.2 Peptide & Protein Drugs 624

8.2.1 Background 624

8.2.2 Target Strategies of Peptide and Protein Drugs 625

8.3 Antibodies 630

8.3.1 Background 630

8.3.2 Target Strategies of Antibody Drugs 630

8.4 Nucleic Acid Therapies 634

8.4.1 Background 634

8.4.2 Target Strategies of Nucleic Acid Drugs 635

8.5 Cell & Gene Therapy 637

8.5.1 Background 637

8.5.2 Target Strategies of Cell and Gene Therapy Drugs 638

8.6 Drug Delivery and Nanotechnology 642

8.6.1 Background 642

8.6.2 Target Strategies of Reformulated Drugs 642

8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 645

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator 652

9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 656

9.2 Company Facts and Ranking 658

9.3 Competitive Fall-Out Assessment 666

9.4 AB Science 668

9.5 Abbott 670

9.6 Active Biotech 673

9.7 Advantagene 675

9.8 Advaxis 678

9.9 Aegera 681

9.10 Aida Pharmaceuticals 683

9.11 Amgen 685

9.12 Antisense Pharma 690

9.13 Anza Therapeutics 692

9.14 Apogee Biotechnology 694

9.15 Apotex 696

9.16 Ardea Biosciences 698

9.17 Ariad 701

9.18 ArQule 703

9.19 Array BioPharma 705

9.20 Astellas 709

9.21 AstraZeneca 714

9.22 AVEO 719

9.23 AVI BioPharma 721

9.24 Bayer 724

9.25 Betapharma 727

9.26 Biogen Idec 730

9.27 Bionovo 733

9.28 BioNumerik 735

9.29 BioSante 738

9.30 Boehringer Ingelheim 740

9.31 Bristol-Myers Squibb 742

9.32 BTG 747

9.33 Calando Pharmaceuticals 751

9.34 Cancer Advances 753

9.35 Cancer Research Technology 755

9.36 Celera 757

9.37 Celgene 759

9.38 Cell Therapeutics 763

9.39 Celldex Therapeutics 766

9.40 Celsion 769

9.41 Celtic Pharma 772

9.42 Center of Molecular Immunology 774

9.43 CG Therapeutics 777

9.44 CompleGen 780

9.45 Cornerstone Pharmaceuticals 782

9.46 CritiTech 784

9.47 Curaxis 787

9.48 Curis 789

9.49 Cyclacel 791

9.50 Cylene Pharmaceuticals 793

9.51 Cynvec 795

9.52 CytImmune Sciences 797

9.53 Cytokinetics 799

9.54 CytRx 801

9.55 Daiichi Sankyo 804

9.56 Dara Biosciences 809

9.57 EGEN Inc 811

9.58 Eisai 813

9.59 Eli Lilly 818

9.60 EntreMed 823

9.61 Epeius Biotechnologies 825

9.62 EpiCept 827

9.63 Esperance Pharmaceuticals 830

9.64 Exelixis 832

9.65 FibroGen 834

9.66 Galectin Therapeutics 836

9.67 Genta 839

9.68 GenVec 841

9.69 Geron 843

9.70 GlaxoSmithKline 845

9.71 GlycoGenesys 850

9.72 Hoffmann-La Roche 852

9.73 Human Genome Sciences 858

9.74 ImmunoCellular Therapeutics 860

9.75 ImmunoGen 862

9.76 Immunomedics 865

9.77 ImmuPharma 869

9.78 Immutep 871

9.79 Innate Pharma 873

9.80 Innovive 875

9.81 Insmed 878

9.82 Insys Therapeutics 881

9.83 Introgen Therapeutics 887

9.84 Ipsen 889

9.85 Johnson & Johnson 892

9.86 Kadmon 894

9.87 Kyowa Hakko Kirin 896

9.88 Leo 898

9.89 Mbiotec 900

9.90 Meda 902

9.91 MediGene 904

9.92 Medisyn Technologies 908

9.93 Merck & Co 910

9.94 Merck KGaA 914

9.95 Merrimack 918

9.96 Mersana Therapeutics 921

9.97 MethylGene 924

9.98 Micromet 926

9.99 Nektar Therapeutics 928

9.100 Nereus Pharmaceuticals 931

9.101 Nippon Kayaku 933

9.102 Nippon Shinyaku 936

9.103 Non-industrial Source 938

9.104 Novacea 941

9.105 NovaLead 944

9.106 Novartis 947

9.107 Novogen 953

9.108 OncoMed 955

9.109 OncoTherapy Science 957

9.110 Oncothyreon 959

9.111 Oncozyme Pharma 961

9.112 Oxford BioMedica 963

9.113 OXiGENE 965

9.114 Paladin Labs 967

9.115 PanaGin 970

9.116 Patrys 972

9.117 Pepscan Therapeutics 974

9.118 Pfizer 976

9.119 Pharmacyclics 983

9.120 PharmaMar 985

9.121 Pharmexa 987

9.122 Pierre Fabre 990

9.123 Piramal 993

9.124 ProMetic Life Sciences 995

9.125 Protgen 997

9.126 Ras Therapeutics 999

9.127 Reata Pharmaceuticals 1001

9.128 Regeneron 1003

9.129 Regulon 1005

9.130 RESprotect 1007

9.131 Rexahn 1009

9.132 Rigel 1012

9.133 Rottapharm Madaus 1014

9.134 Samyang 1017

9.135 Sanofi 1021

9.136 Santaris Pharma 1026

9.137 Shire 1028

9.138 SuperGen 1030

9.139 Taiho 1034

9.140 Takeda 1038

9.141 Talon Therapeutics 1040

9.142 Tapestry Pharmaceuticals 1043

9.143 Tau Therapeutics 1046

9.144 Teva 1048

9.145 Thallion Pharmaceuticals 1050

9.146 Therion Biologics 1052

9.147 Titan Pharmaceuticals 1054

9.148 TopoTarget 1057

9.149 Tragara Pharmaceuticals 1060

9.150 Trion Pharma 1062

9.151 UMN Pharma 1064

9.152 VaxOnco 1066

9.153 Vertex Pharmaceuticals 1068

9.154 Vion Pharmaceuticals 1070

9.155 VioQuest 1072

9.156 ViroMed 1075

9.157 Wilex 1078

9.158 Xerion 1080

9.159 Yakult Honsha 1082

9.160 YM BioSciences 1085

9.161 Zeria 1088

Disclaimer 1090

10 Drug Index 1091

11 Company Index 1098

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 361

Figure 2: The Drug-Target Competitive Landscape of Pancreatic Cancer Drugs - Large Clusters 363

Figure 3: The Drug-Target Competitive Landscape Pancreatic Cancer Drugs - Smaller Clusters 364

Figure 4: Head-to-Head Targeting Competitive Landscape of Pancreatic Cancer Drugs 365

Figure 5: Distribution of Compound Strategies among Pancreatic Cancer Drugs 645

Figure 6: Primary Sub-cellular Localization of Drug Targets 646

Figure 7: Number of Companies per Ranking Level 661

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7

Table 2: Breakdown of the Included Pancreatic Cancer Drug Pipeline by Stage of Development 27

Table 3: Head to Head Target Competition among Pancreatic Cancer Drugs 27

Table 4: Overview of Drug Target Strategy Themes 32

Table 5: Terminally Ceased Targets of Pancreatic Cancer Drugs 33

Table 6: Official Gene Symbol to Target Profle 34

Table 7: Targets of Pancreatic Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 349

Table 8: Identity of Drug Targets with Available Biological Structures 354

Table 9: Number of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 359

Table 10: Available Protein Expression Profiles of Pancreatic Cancer Drug Targets 366

Table 11: Pathway Summary 371

Table 12: Drug Targets without any Identified Assigned Pathways 371

Table 13: Pathway Profiles According to BioCarta of Pancreatic Cancer Drug Targets 373

Table 14: Pathway Profiles According to KEGG of Pancreatic Cancer Drug Targets 392

Table 15: Pathway Profiles According to NetPath of Pancreatic Cancer Drug Targets 415

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 423

Table 17: Top Competitive Target Strategies of Pancreatic Cancer Drugs 424

Table 18: New and Unique Target Strategies of Registered and Marketed Pancreatic Cancer Drugs 425

Table 19: The Competition Through Close Mechanistic Approximation Between Pancreatic Cancer Drugs in Registered to Marketed 425

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Pancreatic Cancer Drugs 426

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Pancreatic Cancer Drugs 427

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Pancreatic Cancer Drugs 428

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Pancreatic Cancer Drugs 431

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Pancreatic Cancer Drugs 433

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Pancreatic Cancer Drugs 435

Table 26: New and Unique Target Strategies in Preclinical Development of Pancreatic Cancer Drugs 436

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Pancreatic Cancer Drugs 437

Table 28: Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 438

Table 29: Connecting Target Strategy with Its Profile Identification Number 440

Table 30: The Competition Through Close Mechanistic Approximation Among Pancreatic Cancer Drugs 609

Table 31: Overview of Compound Strategy Competition Among Pancreatic Cancer Drugs 614

Table 32: Overview of the Competitive Landscape of Small Molecule Based Pancreatic Cancer Drugs 616

Table 33: Competitive Comparison of Target Strategies of Small Molecule Pancreatic Cancer Drugs 617

Table 34: Pursued Target Strategies of Small Molecule Drugs Based Pancreatic Cancer Drugs 619

Table 35: Overview of the Competitive Landscape of Peptide Based Pancreatic Cancer Drugs 625

Table 36: Competitive Comparison of Target Strategies of Peptide Based Pancreatic Cancer Drugs 626

Table 37: Pursued Target Strategies of Peptide Based Pancreatic Cancer Drugs 626

Table 38: Overview of the Competitive Landscape of Protein Based Pancreatic Cancer Drugs 628

Table 39: Pursued Target Strategies of Protein Based Pancreatic Cancer Drugs 629

Table 40: Overview of the Competitive Landscape of Antibody Based Pancreatic Cancer Drugs 630

Table 41: Competitive Comparison of Target Strategies of Antibody Based Pancreatic Cancer Drugs 631

Table 42: Pursued Target Strategies of Antibody Based Pancreatic Cancer Drugs 632

Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Pancreatic Cancer Drugs 635

Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Pancreatic Cancer Drugs 636

Table 45: Pursued Target Strategies of Nucleic Acid Based Pancreatic Cancer Drugs 636

Table 46: Potential Forms of Cell Therapy 637

Table 47: Vectors in Gene Therapy 638

Table 48: Overview of the Competitive Landscape of Cell Therapy Based Pancreatic Cancer Drugs 638

Table 49: Pursued Target Strategies of Cell Therapy Based Pancreatic Cancer Drugs 639

Table 50: Overview of the Competitive Landscape of Gene Therapy Based Pancreatic Cancer Drugs 640

Table 51: Competitive Comparison of Target Strategies of Gene Therapy Based Pancreatic Cancer Drugs 641

Table 52: Pursued Target Strategies of Gene Therapy Based Pancreatic Cancer Drugs 641

Table 53:Overview of the Competitive Landscape of Reformulated Pancreatic Cancer Drugs 642

Table 54: Competitive Comparison of Target Strategies of Reformulated Pancreatic Cancer Drugs 643

Table 55: Pursued Target Strategies of Reformulated Pancreatic Cancer Drugs 644

Table 56: Compound Strategies based on Sub-Cellular Localization of Pancreatic Cancer Drug Targets 646

Table 57: Competitive Summary by Investigator of Pancreatic Cancer Drug Development 652

Table 58: Summary Table of Corporate Changes in the Competitive Landscape of Pancreatic Cancer Drug Development 656

Table 59: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 660

Table 60: Example of a Competitive Fall-Out Table (Targeting TYMS/Modified) 666

Table 61: AB Science's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 669

Table 62: Abbott's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 672

Table 63: Active Biotech's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 674

Table 64: Advantagene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 677

Table 65: Advaxis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 680

Table 66: Aegera's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 682

Table 67: Aida Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 684

Table 68: Amgen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 687

Table 69: Antisense Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 691

Table 70: Anza Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 693

Table 71: Apogee Biotechnology's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 695

Table 72: Apotex's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 697

Table 73: Ardea Biosciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 700

Table 74: Ariad's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 702

Table 75: ArQule's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 704

Table 76: Array BioPharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 707

Table 77: Astellas' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 711

Table 78: AstraZeneca's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 716

Table 79: AVEO's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 720

Table 80: AVI BioPharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 723

Table 81: Bayer's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 725

Table 82: Betapharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 729

Table 83: Biogen Idec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 732

Table 84: Bionovo's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 734

Table 85: BioNumerik's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 737

Table 86: BioSante's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 739

Table 87: Boehringer Ingelheim's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 741

Table 88: Bristol-Myers Squibb's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 744

Table 89: BTG's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 749

Table 90: Calando Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 752

Table 91: Cancer Advances' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 754

Table 92: Cancer Research Technology's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 756

Table 93: Celera's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 758

Table 94: Celgene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 761

Table 95: Cell Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 765

Table 96: Celldex Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 768

Table 97: Celsion's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 771

Table 98: Celtic Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 773

Table 99: Center of Molecular Immunology's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 776

Table 100: CG Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 779

Table 101: CompleGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 781

Table 102: Cornerstone Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 783

Table 103: CritiTech's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 786

Table 104: Curaxis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 788

Table 105: Curis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 790

Table 106: Cyclacel's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 792

Table 107: Cylene Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 794

Table 108: Cynvec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 796

Table 109: CytImmune Sciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 798

Table 110: Cytokinetics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 800

Table 111: CytRx's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 803

Table 112: Daiichi Sankyo's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 807

Table 113: Dara Biosciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 810

Table 114: EGEN Inc's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 812

Table 115: Eisai's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 815

Table 116: Eli Lilly's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 820

Table 117: EntreMed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 824

Table 118: Epeius Biotechnologies' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 826

Table 119: EpiCept's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 829

Table 120: Esperance Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 831

Table 121: Exelixis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 833

Table 122: FibroGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 835

Table 123: Galectin Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 838

Table 124: Genta's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 840

Table 125: GenVec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 842

Table 126: Geron's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 844

Table 127: GlaxoSmithKline's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 847

Table 128: GlycoGenesys' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 851

Table 129: Hoffmann-La Roche's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 854

Table 130: Human Genome Sciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 859

Table 131: ImmunoCellular Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 861

Table 132: ImmunoGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 864

Table 133: Immunomedics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 867

Table 134: ImmuPharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 870

Table 135: Immutep's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 872

Table 136: Innate Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 874

Table 137: Innovive's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 877

Table 138: Insmed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 880

Table 139: Insys Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 884

Table 140: Introgen Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 888

Table 141: Ipsen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 891

Table 142: Johnson & Johnson's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 893

Table 143: Kadmon's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 895

Table 144: Kyowa Hakko Kirin's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 897

Table 145: Leo's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 899

Table 146: Mbiotec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 901

Table 147: Meda's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 903

Table 148: MediGene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 906

Table 149: Medisyn Technologies' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 909

Table 150: Merck & Co's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 912

Table 151: Merck KGaA's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 916

Table 152: Merrimack's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 920

Table 153: Mersana Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 923

Table 154: MethylGene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 925

Table 155: Micromet's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 927

Table 156: Nektar Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 930

Table 157: Nereus Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 932

Table 158: Nippon Kayaku's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 935

Table 159: Nippon Shinyaku's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 937

Table 160: Non-industrial source's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 940

Table 161: Novacea's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 943

Table 162: NovaLead's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 946

Table 163: Novartis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 949

Table 164: Novogen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 954

Table 165: OncoMed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 956

Table 166: OncoTherapy Science's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 958

Table 167: Oncothyreon's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 960

Table 168: Oncozyme Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 962

Table 169: Oxford BioMedica's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 964

Table 170: OXiGENE's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 966

Table 171: Paladin Labs' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 969

Table 172: PanaGin's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 971

Table 173: Patrys' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 973

Table 174: Pepscan Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 975

Table 175: Pfizer's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 978

Table 176: Pharmacyclics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 984

Table 177: PharmaMar's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 986

Table 178: Pharmexa's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 989

Table 179: Pierre Fabre's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 992

Table 180: Piramal's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 994

Table 181: ProMetic Life Sciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 996

Table 182: Protgen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 998

Table 183: Ras Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1000

Table 184: Reata Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1002

Table 185: Regeneron's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1004

Table 186: Regulon's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1006

Table 187: RESprotect's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1008

Table 188: Rexahn's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1011

Table 189: Rigel's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1013

Table 190: Rottapharm Madaus' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1016

Table 191: Samyang's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1019

Table 192: Sanofi's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1023

Table 193: Santaris Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1027

Table 194: Shire's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1029

Table 195: SuperGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1032

Table 196: Taiho's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1036

Table 197: Takeda's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1039

Table 198: Talon Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1042

Table 199: Tapestry Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1045

Table 200: Tau Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1047

Table 201: Teva's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1049

Table 202: Thallion Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1051

Table 203: Therion Biologics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1053

Table 204: Titan Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1056

Table 205: TopoTarget's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1059

Table 206: Tragara Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1061

Table 207: Trion Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1063

Table 208: UMN Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1065

Table 209: VaxOnco's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1067

Table 210: Vertex Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1069

Table 211: Vion Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1071

Table 212: VioQuest's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1074

Table 213: ViroMed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1077

Table 214: Wilex's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1079

Table 215: Xerion's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1081

Table 216: Yakult Honsha's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1084

Table 217: YM BioSciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1087

Table 218: Zeria's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1089

To order this report:

Drug and Medication Industry: Commercializing Pancreatic Cancer Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nbo@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker